Author: Melina Rodriguez, CST/CMA/CCA

Sarclisa Is Already Approved for Multiple Myeloma. Now Sanofi Wants to Deliver It Without the IV. The Phase 3 Evidence Behind That Ambition.

📌 The essentials On April 22, 2026, Sanofi announced that the FDA extended by up to three months the target action date for its review of Sarclisa subcutaneous (SC), a new formulation of isatuximab-irfc (Sarclisa) designed to replace IV infusion with an on-body injector (OBI). The revised PDUFA date is July 23, 2026. The extension is a delay, not a rejection. The clinical basis: The Phase 3 IRAKLIA trial (NCT05405166), published in the Journal of Clinical Oncology, demonstrated non-inferiority of Sarclisa SC versus Sarclisa IV across all co-primary and key secondary endpoints, including a striking reduction in infusion-related reactions from 25% (IV) to 1.5% (SC). EU status: The EMA’s CHMP issued a positive opinion recommending approval of Sarclisa SC on March 26, 2026. If the FDA approves, Sarclisa SC would become the first anticancer treatment ever administered through an on-body injector.

Multiple myeloma is the second most common blood cancer. It is not curable for most patients, which means that the drugs used to treat it and the manner in which they are delivered become part of a patient’s life for the long term. Infusion-based regimens, administered intravenously in a clinical setting, require patients to spend hours in infusion chairs, sometimes repeatedly across months or years of treatment. For a drug like Sarclisa (isatuximab-irfc), which is given weekly during the first treatment cycle and biweekly thereafter, that burden is substantial and ongoing.

On April 22, 2026, Sanofi announced that the FDA has extended by up to three months the target action date for its review of Sarclisa subcutaneous (SC), a new formulation designed to replace the IV infusion with an on-body injector, or OBI. The revised PDUFA date is July 23, 2026. The extension is a delay, not a rejection. The clinical evidence package behind it, built on the Phase 3 IRAKLIA trial, is solid, and the European Medicines Agency’s CHMP has already issued a positive opinion recommending approval. If the FDA ultimately approves Sarclisa SC, it would become the first anticancer treatment ever administered through an on-body injector.

This post covers what Sarclisa is and why it matters in the myeloma treatment landscape, what the OBI is and how it works, what IRAKLIA showed, what the FDA extension means in practice, and where EU and U.S. regulatory timelines stand.

What Is Sarclisa and What Is It Already Approved For?

Sarclisa (isatuximab-irfc) is an anti-CD38 monoclonal antibody. CD38 is a surface protein that is highly and uniformly expressed on the surface of multiple myeloma cells, making it a well-validated therapeutic target. By binding to a specific epitope on the CD38 receptor, Sarclisa triggers multiple antitumor mechanisms: direct induction of programmed cell death (apoptosis), antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity. It also modulates immune cells in the tumor microenvironment.

In the U.S., Sarclisa is currently approved in its intravenous formulation across three indications:

Indication	Combination partner(s)	Approval year
Relapsed/refractory MM, 2 or more prior lines including lenalidomide and a proteasome inhibitor	Pomalidomide + dexamethasone (Isa-Pd)	2020
Relapsed/refractory MM, 1 to 3 prior lines	Carfilzomib + dexamethasone (Isa-Kd)	2021
Newly diagnosed MM, transplant-ineligible	Bortezomib + lenalidomide + dexamethasone (Isa-VRd)	2024

Sarclisa has been approved in more than 60 countries and prescribed to more than 60,000 patients worldwide. The VRd combination approved in 2024 was particularly significant: it made Sarclisa the first anti-CD38 therapy indicated with a standard-of-care triplet regimen for newly diagnosed, transplant-ineligible patients, an earlier and larger patient population than the relapsed/refractory settings covered by earlier approvals.

All three approved regimens are currently administered as intravenous infusions. The first dose of Sarclisa IV typically requires several hours; even after subsequent dose acceleration, appointments remain multi-hour commitments. For a patient who will receive Sarclisa across multiple treatment cycles, potentially for years, that time burden accumulates significantly.

What Is the On-Body Injector and Why Does It Matter?

The on-body injector (OBI) at the center of this BLA is the enFuse device, developed by Enable Injections. Understanding what it is and how it differs from standard subcutaneous injections explains both the clinical rationale and the novelty of what Sanofi is seeking to bring to market.

Standard subcutaneous injection of a biologic drug involves a healthcare provider manually pushing a syringe or autoinjector to deliver the medication into the tissue just beneath the skin. For biologics that require large volumes of fluid, manual subcutaneous injection can be uncomfortable and slow. The enFuse OBI takes a different approach.

How the enFuse on-body injector works The enFuse is a small, flat wearable device applied to the skin surface, typically the arm, like a patch. It uses automated delivery technology to administer the drug subcutaneously at a controlled, constant rate rather than requiring manual force from a clinician. Key features: Hands-free delivery: once applied and activated, the device operates automatically and the patient can move around. Fixed dose: Sarclisa SC is given at a flat dose of 1,400 mg, eliminating the weight-based calculation required for IV dosing (10 mg/kg). Small retractable needle: thinner than current subcutaneous injection needles with low local trauma. No electronics or batteries: purely mechanical, single-use operation. Discreet: worn under clothing during administration. The device is prefilled by clinical staff and then applied to the patient. Administration time is substantially shorter than IV infusion.

For patients with multiple myeloma who receive treatment continuously until disease progression, the practical difference between IV and OBI administration is material. IV infusion requires a patient to sit in an infusion chair, tethered to an IV pole, for an extended period. OBI administration means the drug can be delivered while the patient is mobile, with no IV line, no infusion chair, and a substantially shorter clinic stay.

This is not cosmetic. The published literature on cancer treatment burden consistently shows that infusion-related time and logistical demands are among the leading factors affecting treatment adherence and quality of life for patients on long-term oncology regimens. A delivery format that preserves efficacy while reducing clinic time and physical constraints is a meaningful clinical advance, not merely a convenience.

The IRAKLIA Trial: What the Evidence Shows

The BLA for Sarclisa SC is supported primarily by the Phase 3 IRAKLIA study (NCT05405166), published in the Journal of Clinical Oncology and presented at the 2025 ASCO Annual Meeting and European Hematology Association Congress. IRAKLIA is the first Phase 3 myeloma trial designed to evaluate on-body injector delivery of a cancer treatment.

Study design

IRAKLIA enrolled 531 adults with relapsed/refractory multiple myeloma who had received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. Patients were randomized 1:1 to:

Sarclisa SC via OBI at 1,400 mg fixed dose plus pomalidomide plus dexamethasone (SC arm, n=263)
Sarclisa IV at 10 mg/kg weight-based dose plus pomalidomide plus dexamethasone (IV arm, n=268)

Both arms followed the same dosing schedule: weekly for the first treatment cycle, then biweekly. The trial was designed to establish non-inferiority of the SC formulation, meaning the goal was to demonstrate that SC delivery was not meaningfully worse than IV, not that it was superior to it.

The two co-primary endpoints were objective response rate (ORR) and drug concentration at steady state (Ctrough), addressing both clinical efficacy and pharmacokinetic equivalence.

Results

Endpoint	Sarclisa SC (OBI)	Sarclisa IV	Non-inferiority met?
ORR (overall response rate)	71.1%	70.5%	Yes (RR 1.008; 95% CI 0.903 to 1.126; p=0.0006)
Ctrough at steady state (C6D1)	GMR 1.532 (90% CI 1.316 to 1.784)	Reference	Yes (lower CI above 0.8 NI margin)
Ctrough at cycle 2 (key secondary)	GMR 1.302 (95% CI 1.158 to 1.465)	Reference	Yes (lower CI above 0.8 NI margin)
VGPR or better (key secondary)	Similar between arms	Similar between arms	Yes (NI met)
Infusion-related reactions	1.5%	25%	N/A, significant reduction favoring SC

Source: Ailawadhi S et al. Journal of Clinical Oncology. 2025. doi:10.1200/JCO-25-00744

All four co-primary and key secondary endpoints were met. The response depth was comparable between arms, including similar rates of very good partial response (VGPR) and better, stringent complete response, and complete response. The safety profile showed no new or unexpected signals. Notably, the drug concentration in the SC arm was actually somewhat higher than in the IV arm at steady state, meaning the non-inferiority requirement was easily met from both directions.

The most striking secondary finding was the infusion-related reaction (IRR) rate: 1.5% in the SC arm versus 25% in the IV arm. Infusion reactions are one of the most common and disruptive complications of IV biologic therapy, sometimes requiring dose interruptions, premedication, prolonged monitoring, or clinical intervention. A roughly 16-fold reduction in IRR rate is clinically meaningful and directly relevant to patient experience and healthcare resource use.

Patient preference data from the companion IZALCO Phase 2 study, which evaluated Sarclisa SC with carfilzomib and dexamethasone, found that approximately 75% of patients preferred OBI delivery over manual subcutaneous injection.

The lead investigator for IRAKLIA, Dr. Xavier Leleu of Hôpital La Mileterie in Poitiers, France, characterized the trial in the JCO publication as the first Phase 3 multiple myeloma study to incorporate hands-free OBI technology, noting the implications for both practice efficiency and patient convenience.

What a Three-Month FDA Extension Actually Means

The April 22 announcement describes a standard FDA procedural action. Here is what it does and does not mean:

What it is	What it is not
A routine extension of the PDUFA review clock by up to three months	A Complete Response Letter or rejection
Common for complex biologics where the FDA needs additional time to complete its review	A signal of clinical deficiency in the evidence package
Moves the target action date from the original deadline to July 23, 2026	An indication that the BLA will not be approved
A standard regulatory mechanism used across many drug applications	Unique to Sarclisa or indicative of a problem specific to this program

Sanofi has not disclosed the specific reason for the extension, which is typical. These extensions can arise from FDA requests for additional data or clarifications, manufacturing inspection scheduling, or the complexity of a novel delivery platform requiring more thorough review.

The most relevant context is the EU trajectory. The EMA’s CHMP issued a positive opinion recommending approval of Sarclisa SC on March 26, 2026, less than a month before the FDA extension announcement. The CHMP recommendation covers both the OBI and manual injection formats. A positive CHMP opinion nearly always results in European Commission approval, which is expected in the coming months. That the most rigorous equivalent of the FDA review process in Europe has already concluded favorably is a meaningful indicator of where the clinical package stands.

Why the EU positive opinion matters for the U.S. review The CHMP’s positive opinion is based on the same IRAKLIA Phase 3 dataset supporting the U.S. BLA. CHMP review is scientifically independent from the FDA, conducted by a committee of European member state experts. A positive CHMP opinion based on the same evidence that the FDA is currently reviewing does not guarantee FDA approval, but it does establish that the clinical and safety package met the rigorous evidentiary standards of another leading regulatory authority. For patients and providers tracking this BLA, the EU recommendation is relevant evidence about where the clinical program stands.

Where This Fits in the Broader Myeloma Treatment Landscape

Multiple myeloma treatment has advanced substantially over the past decade. The introduction of proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (lenalidomide, pomalidomide), anti-CD38 monoclonal antibodies (daratumumab, isatuximab), and more recently BCMA-directed therapies (belantamab mafodotin, teclistamab, idecabtagene vicleucel, ciltacabtagene autoleucel) has transformed a disease that once had a median survival of 2 to 3 years into one where many patients survive 10 years or longer.

With longer survival, treatment becomes a longer-term proposition, and the cumulative burden of repeated clinic visits, infusions, and associated time commitments grows accordingly. The pivot toward more convenient administration formats is a deliberate industry and clinical trend, not specific to Sarclisa.

The anti-CD38 class is the most direct competitive context. Daratumumab (Darzalex), made by Johnson and Johnson, is the dominant anti-CD38 therapy in the myeloma market and is already available in a subcutaneous formulation (Darzalex Faspro), approved in 2020. Daratumumab SC uses the Halozyme ENHANZE co-formulation with hyaluronidase, which is different from the OBI platform Sanofi is pursuing for isatuximab. Both approaches aim to solve the same clinical problem: reducing the infusion burden of IV anti-CD38 antibody therapy.

Sarclisa SC vs. Darzalex Faspro: Comparing administration approaches Darzalex Faspro (daratumumab SC) is co-formulated with hyaluronidase-fihj, which breaks down hyaluronic acid in subcutaneous tissue to allow the drug to disperse and be absorbed. Administration is via manual subcutaneous injection, taking approximately 3 to 5 minutes. Sarclisa SC OBI would use the enFuse wearable device for automated, hands-free delivery. The fixed 1,400 mg dose eliminates weight-based calculation. The OBI technology has not been used previously for any approved anticancer therapy. If approved, Sarclisa SC OBI would be the first anticancer treatment ever delivered via on-body injector, a genuinely new delivery format in oncology, not merely an incremental modification of existing subcutaneous techniques.

For oncologists and hematologists managing patients on long-term anti-CD38 therapy, the choice between formulations will be influenced by institutional experience, patient preference, payer formulary structure, and dosing logistics. The clinical efficacy evidence for both daratumumab SC and isatuximab SC is strong, with non-inferiority to IV demonstrated for each. The OBI differentiator for Sarclisa is the hands-free, automated delivery format and the substantially lower infusion reaction rate (1.5% versus 25% in IRAKLIA), which may influence provider and patient preference in a competitive market.

What to Watch For: Indications and Timeline

The Sarclisa SC BLA covers all currently approved U.S. indications for the IV formulation, meaning the three approved regimens (Isa-Pd, Isa-Kd, and Isa-VRd) could all become available in the SC formulation if approved. This reflects the IRAKLIA data demonstrating consistent efficacy and safety across the pharmacokinetic parameters likely applicable to all combinations.

The revised PDUFA date is July 23, 2026. This is a target action date, not a guaranteed approval date. The FDA could approve, issue a Complete Response Letter, or request additional information by or around that date. Given the clean Phase 3 data and the EU positive opinion, the direction of the BLA appears favorable, but no approval is certain until it occurs.

The CHMP recommendation in Europe covers both the OBI and manual injection formats, meaning the EU label, if issued, will be broader than what the U.S. BLA has described publicly. Whether Sanofi plans to seek manual injection approval in the U.S. as well has not been specifically disclosed.

For patients currently on Sarclisa IV who are interested in the SC formulation, no action is needed now. If and when the FDA approves Sarclisa SC, the transition from IV to SC would be a clinical decision made with a treating hematologist, considering individual patient circumstances, tolerability, and the available combinations at that time. Clinical teams should monitor the July 23, 2026 decision window.

Multiple myeloma is a disease that most patients live with for years, and the treatment experience across those years matters as much as the clinical outcomes in any single trial. Sarclisa SC, backed by robust Phase 3 non-inferiority data and a European positive opinion, represents a meaningful step toward a less burdensome treatment experience for patients who rely on anti-CD38 therapy. The three-month FDA extension is a procedural delay, not a clinical verdict. The July 23 PDUFA date is the one to watch.

For related coverage on advances in delivery technology and oncology approvals in 2026, see our post on the first FDA approval of a subcutaneous formulation for myasthenia gravis (VYVGART Hytrulo) and our analysis of Dato-DXd and the ADC approach in triple-negative breast cancer.

Sources

Sanofi press release (FDA extension): Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US. April 22, 2026. sanofi.com.

Sanofi press release (CHMP opinion): Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP. March 27, 2026. sanofi.com.

IRAKLIA Phase 3 primary publication: Ailawadhi S et al. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 2025. doi:10.1200/JCO-25-00744

IRAKLIA trial registration: NCT05405166. ClinicalTrials.gov.

EMA SARCLISA EPAR: Sarclisa: EPAR product information. EMA.europa.eu.

Sarclisa IV original FDA approval (Isa-Pd): FDA approves isatuximab-irfc for multiple myeloma. FDA.gov. March 2020.

Sarclisa IV approval (Isa-Kd): FDA approves isatuximab-irfc with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma. FDA.gov. March 2021.

Sarclisa IV approval (Isa-VRd): FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. FDA.gov. October 2024.

Darzalex Faspro FDA approval: FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma. FDA.gov. May 2020.

CancerNetwork coverage: FDA Delays Decision on Subcutaneous Isatuximab in Multiple Myeloma. cancernetwork.com. April 2026.

Targeted Oncology: IRAKLIA Trial Validates Subcutaneous Isatuximab in Multiple Myeloma. targetedonc.com.

OncLive: IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma. onclive.com.

International Myeloma Foundation: CHMP-EMA Recommends Approval of Sarclisa Subcutaneous Formulation via On-Body Injector. myeloma.org. March 2026.

Patient resources: International Myeloma Foundation | Multiple Myeloma Research Foundation | American Cancer Society: Multiple Myeloma | ClinicalTrials.gov: multiple myeloma

Disclaimer: Health Evidence Digest provides general information about FDA regulatory updates and health research for educational purposes. This content is not a substitute for professional medical advice. Sarclisa (isatuximab-irfc) subcutaneous formulation is not currently FDA-approved; the BLA is under review with a target action date of July 23, 2026. Decisions about cancer treatment regimens should be made in consultation with a qualified, board-certified hematologist or oncologist.

April 29, 2026

A New Kind of Botox That Wears Off in Weeks Just Hit a Regulatory Snag. Here’s What That Means and What Patients Considering Neurotoxins Actually Need to Know.

📌 The essentials On April 23, 2026, AbbVie announced it received a Complete Response Letter (CRL) from the FDA for its Biologics License Application for TrenibotE (trenibotulinumtoxinE), a new short-acting aesthetic neurotoxin using botulinum toxin serotype E. The FDA’s concerns are exclusively manufacturing-related. No safety issues. No clinical deficiencies. No new clinical trials required. This is the kind of CRL that companies routinely resolve in months. The clinical data package is intact: two pivotal Phase 3 trials enrolling more than 2,100 patients, all primary and secondary endpoints met. What TrenibotE would offer: onset as early as 8 hours post-injection, effects lasting 2 to 3 weeks rather than 3 to 4 months. It is the first botulinum toxin serotype E product to seek FDA approval for aesthetic use, and it is specifically designed for patients who have been hesitant to try neurotoxins because of concerns about committing to a long-lasting outcome. Using this CRL as a starting point, this post covers what TrenibotE is, where it fits in the neurotoxin landscape, and what patients considering any neurotoxin treatment need to know right now.

If you have been curious about neurotoxin treatments but hesitant to commit to effects that last three or four months, a new option has been in development specifically designed for you. TrenibotE (trenibotulinumtoxinE), AbbVie’s experimental short-acting neurotoxin, is a botulinum toxin serotype E that kicks in within eight hours and wears off in two to three weeks.

On April 23, 2026, AbbVie announced it received a Complete Response Letter from the FDA for its Biologics License Application. This is a regulatory setback that delays but does not derail approval. The FDA’s concerns are manufacturing-related only. No safety issues, no clinical deficiencies, no new studies required. This is the kind of CRL that companies routinely resolve in months.

What Is TrenibotE and Why Does the Duration Matter?

All currently approved aesthetic neurotoxins in the United States, including Botox Cosmetic, Dysport, Xeomin, Jeuveau, and Daxxify, use botulinum neurotoxin serotype A. TrenibotE uses serotype E, a different protein that acts on the same molecular target (the SNARE complex at the neuromuscular junction) but via a different mechanism, producing a meaningfully different pharmacological profile.

Feature	TrenibotE (Serotype E)	Standard Serotype A (Botox Cosmetic etc.)
Onset of effect	As early as 8 hours post-injection	Typically 3 to 5 days (Daxxify: similar to standard)
Duration of effect	2 to 3 weeks	3 to 4 months (Daxxify: up to 6 months)
Serotype	Botulinum neurotoxin type E	Botulinum neurotoxin type A
FDA status	BLA under review; CRL received April 2026 (manufacturing only)	All approved; available now
Indication studied	Moderate to severe glabellar lines (frown lines)	Multiple facial areas depending on product
Clinical program size	More than 2,100 patients across Phase 3 trials; all endpoints met	Extensive; decades of real-world safety data
Target patient	First-timers wanting a trial; patients preferring flexibility	General aesthetic neurotoxin candidates

The short duration is the differentiator. AbbVie has positioned TrenibotE specifically for patients who have been reluctant to try neurotoxins because they fear committing to an outcome they might not like. With effects lasting two to three weeks rather than three to four months, a first-time patient who does not like the results can simply wait it out. That is a meaningful psychological and practical barrier removed.

AbbVie’s own research found that fear of looking unnatural is one of the most significant barriers to first-time neurotoxin use. A short-acting option directly addresses this. For existing neurotoxin users who want more frequent control over their appearance, or for use in areas where very precise and temporary effect management is desirable, TrenibotE may also find a clear role.

Why a manufacturing CRL is not a clinical concern A Complete Response Letter is the FDA’s mechanism for identifying deficiencies in a BLA before approval. Receiving one does not mean the drug does not work or is not safe. It means specific issues must be addressed. In this case, the FDA’s concerns are exclusively chemistry, manufacturing, and controls (CMC) — the processes by which the drug is made, tested for consistency, and verified for quality. CMC CRLs are common for complex biologics and typically resolved without new clinical trials, as AbbVie has confirmed is the case here. The clinical data package is intact: two pivotal Phase 3 trials enrolling more than 2,100 patients, all primary and secondary endpoints met, adverse event rates similar to placebo. The FDA has not questioned any of this. TrenibotE’s clinical approval path is not in doubt, only the timeline.

AbbVie’s Full Neurotoxin Portfolio: What’s Already Available

AbbVie is the dominant company in the aesthetic neurotoxin market, primarily through its Botox franchise, which it acquired as part of its 2020 purchase of Allergan. Understanding what AbbVie already offers helps situate where TrenibotE would fit.

Botox Cosmetic (onabotulinumtoxinA)

The original and most widely used neurotoxin in aesthetic medicine, with over 30 years of clinical use. Botox Cosmetic is FDA-approved for the temporary improvement of moderate to severe glabellar lines (frown lines between the brows), forehead lines, and crow’s feet. It typically takes 3 to 5 days to take effect and lasts 3 to 4 months. It is also one of the most studied aesthetic treatments in the world, with an extensive real-world safety dataset.

Botox Cosmetic generated $2.6 billion in global sales in 2025, a 4.3% decline from the prior year, reflecting competitive pressure from newer entrants like Daxxify and market saturation in the core treatment-experienced population. This commercial context is part of why TrenibotE matters strategically for AbbVie: it targets the large population of aesthetics-curious patients who have not yet tried neurotoxin treatment.

BOTOX Therapeutic: The Non-Cosmetic Uses

It is worth noting that botulinum toxin A has a substantial and clinically important therapeutic footprint well beyond wrinkles. BOTOX Therapeutic generated $3.7 billion for AbbVie in 2025 from its medical indications, which include:

Chronic migraine: 15 or more headache days per month, with at least 8 being migraines. Administered every 12 weeks by injection into specific head and neck muscles. One of the most effective preventive treatments for this debilitating condition.
Overactive bladder and urinary incontinence: injected into the bladder muscle by a urologist, reducing urgency and incontinence episodes.
Cervical dystonia: abnormal head position and neck pain caused by involuntary muscle contractions.
Upper limb spasticity: following stroke or other neurological conditions.
Hyperhidrosis: severe primary axillary hyperhidrosis (excessive underarm sweating) unresponsive to topical treatments.
Blepharospasm and strabismus: eye muscle disorders.

These therapeutic applications are relevant because patients who are prescribed BOTOX for medical reasons sometimes ask whether the same drug can be used for cosmetic purposes, and vice versa. The answer is yes, but therapeutic and cosmetic formulations involve different dosing, injection patterns, and billing structures. A prescriber experienced in BOTOX for migraines may or may not be the right provider for cosmetic treatment.

The Full Neurotoxin Landscape: Who Else Is on the Market

The U.S. aesthetic neurotoxin market now has five approved products, with TrenibotE potentially becoming the sixth. Here is a plain-language comparison of what is currently available:

Product	Company	Onset	Duration	Distinctive feature
Botox Cosmetic (onabotulinumtoxinA)	AbbVie	3 to 5 days	3 to 4 months	Original; largest real-world dataset; broadest approved indications
Dysport (abobotulinumtoxinA)	Galderma	2 to 3 days	3 to 4 months	Slightly faster onset; different diffusion profile from Botox
Xeomin (incobotulinumtoxinA)	Merz	3 to 5 days	3 to 4 months	No complexing proteins; may reduce antibody formation risk
Jeuveau (prabotulinumtoxinA-xvfs)	Evolus	2 to 5 days	3 to 4 months	Often priced more competitively; aimed at value-conscious market
Daxxify (daxibotulinumtoxinA-lanm)	Revance	2 to 3 days	Up to 6 months	Longest duration on market; proprietary peptide excipient technology
TrenibotE (trenibotulinumtoxinE)	AbbVie	~8 hours	2 to 3 weeks	Shortest duration; first serotype E; targets first-time/hesitant patients. NOT YET APPROVED.

All approved products are FDA-regulated biologics. Differences in onset and duration are real but modest among the serotype A products; the serotype E distinction of TrenibotE is more significant.

How Neurotoxins Actually Work: The Science Behind the Treatment

Botulinum toxin, produced naturally by the bacterium Clostridium botulinum, is one of the most potent biological substances known. In its raw form at high doses, it causes botulism. In precisely calibrated, highly purified, tiny doses injected into targeted muscles, it is one of the most studied and safest aesthetic treatments in medicine.

The mechanism: botulinum toxin cleaves proteins in the SNARE complex, the molecular machinery that nerve terminals use to release the neurotransmitter acetylcholine. When the toxin is injected into a facial muscle, it temporarily prevents that muscle from receiving the nerve signal telling it to contract. The muscle relaxes. The overlying skin smooths out. The effect is not permanent; eventually, the nerve terminal generates new SNARE proteins, restores its ability to signal, and muscle function returns.

Serotype A and serotype E toxins act on the same SNARE complex but cleave different proteins within it, SNAP-25 for serotype A and SNAP-23 for serotype E, which is why the duration differs. The serotype E cleavage appears to be more rapidly reversed by the cell’s repair machinery, producing the shorter duration.

This is also why the myasthenia gravis contraindication for neurotoxins matters: in MG, the neuromuscular junction is already compromised by autoimmune attack, and adding botulinum toxin can amplify weakness dangerously.

What neurotoxins can and cannot do Neurotoxins work best on dynamic wrinkles, which are lines caused by repeated muscle movement such as frown lines between the brows (glabellar lines), forehead lines, and crow’s feet around the eyes. When the underlying muscle is relaxed, these lines soften or disappear. They are less effective for static wrinkles, which are lines present even at rest caused by volume loss, skin laxity, and collagen degradation over time. These are better addressed by dermal fillers, skin resurfacing, or other interventions. Many patients benefit from a combination approach. Neurotoxins do not address skin texture, pigmentation, pore size, or overall skin quality. They specifically target the muscle activity that creates movement-related lines. Onset, duration, and outcome vary by individual: metabolism, muscle mass, injection technique, and product characteristics all affect how quickly and how long the treatment works for any given person.

Choosing Between Options: What Actually Matters for Patients

Given the range of approved products and TrenibotE waiting in the wings, here are the questions that genuinely matter:

How experienced is your injector?

This is the single most important variable in neurotoxin outcomes, more important than which product is used. Neurotoxin injection is a skill: placement, depth, dosing pattern, and understanding of individual facial anatomy determine whether results look natural or frozen, whether brow position is maintained or affected, and whether asymmetry is corrected or introduced. Board-certified dermatologists, plastic surgeons, oculoplastic surgeons, and facial plastic surgeons with dedicated aesthetic training have the deepest expertise. The American Board of Dermatology and American Board of Plastic Surgery have physician lookup tools.

Duration: longer or shorter?

For patients who are established neurotoxin users and happy with their results, longer-lasting products like Daxxify (up to 6 months) offer fewer clinic visits and potentially better value over time. For first-timers, patients who have had sub-optimal outcomes before, or anyone who values maximum flexibility, shorter duration makes sense. Currently the shortest available lasts 3 to 4 months. TrenibotE would reduce that to 2 to 3 weeks when approved.

What about safety?

All approved neurotoxins share a class-level FDA boxed warning: the toxin may spread beyond the injection site and cause serious symptoms including swallowing and breathing difficulties. This is extremely rare at aesthetic doses and is primarily a concern for therapeutic indications where much higher doses are used in or near the throat and neck. It is a required label warning for all formulations.

Common side effects at aesthetic doses include bruising and swelling at the injection site, headache, and temporary eyelid drooping (ptosis) if the toxin migrates to the levator muscle of the upper eyelid, which is why injector skill and patient positioning matter. Ptosis is temporary and resolves as the toxin wears off.

Neurotoxins should not be used during pregnancy or breastfeeding. Patients with neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS) should not receive botulinum toxin. Certain antibiotics (aminoglycosides) can potentiate the effect and should be discussed with the injecting clinician.

The antibody question

With repeated neurotoxin treatments, a small proportion of patients develop neutralizing antibodies that reduce treatment response over time. This is more common with higher therapeutic doses and less common at aesthetic doses. Xeomin’s “naked toxin” formulation (without complexing proteins) is sometimes selected for patients who show signs of reduced response, on the theory that fewer foreign proteins may lower antibody formation. The clinical evidence base for this theoretical advantage is limited. When TrenibotE arrives, the serotype E mechanism may offer an alternative pathway for patients who have developed antibodies to serotype A products.

AbbVie’s Chief Scientific Officer Dr. Roopal Thakkar described TrenibotE in the company’s April 2026 announcement as an important innovation in botulinum toxin science with the potential to expand options for patients interested in facial aesthetics. The manufacturing CRL does not change the clinical case for the drug.

What AbbVie’s Declining Botox Sales Tell Us About the Market

AbbVie’s total global aesthetics business generated $4.86 billion in 2025, a 6.1% decline from 2024. Botox Cosmetic specifically fell 4.3%. This commercial context illustrates why TrenibotE matters strategically for AbbVie beyond the science.

Multiple factors are contributing to the decline. Competition from Daxxify (Revance) has taken some market share with its longer-duration proposition. The GLP-1 weight loss medications phenomenon has had an indirect aesthetic effect: patients losing significant weight on semaglutide or tirzepatide are experiencing facial volume loss, a pattern sometimes called “Ozempic face,” which shifts demand toward filler products rather than neurotoxins. For more on how GLP-1 medications affect body composition in ways that extend beyond their primary indications, see our post on GLP-1 medications and their effects in women with PCOS. And the treatment-experienced core market is showing signs of saturation.

TrenibotE is AbbVie’s attempt to grow the overall market rather than defend share within it. The target is the large proportion of aesthetics-curious consumers who have never tried neurotoxin treatment and cite long duration as a primary concern. The manufacturing CRL is a setback for that timeline, not a refutation of the strategy. A resubmission is expected in 2026, with potential approval in 2027.

Are you considering a neurotoxin treatment for the first time, or revisiting the decision?

The neurotoxin market has more good options than at any point in its history, and more are coming. For patients considering any neurotoxin treatment right now, the most important factor is not which product is used but who is injecting it. A consultation with a board-certified dermatologist or plastic surgeon with dedicated aesthetic training is the right starting point. The American Society of Plastic Surgeons and American Academy of Dermatology both have practitioner directories.

Sources

AbbVie press release: AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. April 23, 2026. news.abbvie.com

BioPharm International: AbbVie Receives FDA Complete Response Letter for TrenibotulinumtoxinE. biopharminternational.com. April 2026.

PharmExec: FDA Issues CRL to AbbVie for TrenibotulinumtoxinE’s Biologics License Application. pharmexec.com. April 2026.

Plastic Surgery Practice: FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Toxin Application. plasticsurgerypractice.com. April 2026.

Fierce Pharma: FDA snubs AbbVie’s prospective Botox heir amid series of manufacturing-related CRLs. fiercepharma.com. April 2026.

AbbVie financials: AbbVie Full-Year 2025 Financial Results. Global aesthetics $4.86B (down 6.1%); Botox Cosmetic $2.6B (down 4.3%). investor.abbvie.com.

Daxxify FDA approval: FDA approves daxibotulinumtoxinA-lanm for glabellar lines. FDA.gov. September 2022.

Botox Cosmetic prescribing information: Botox Cosmetic full prescribing information. accessdata.fda.gov.

FDA botulinum toxin safety communication: Botulinum Toxin Drug Safety Communication: Updated Warnings. FDA.gov.

Practitioner directories: American Society of Plastic Surgeons | American Academy of Dermatology

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about aesthetic treatments should be made in consultation with a qualified, board-certified medical professional. TrenibotE (trenibotulinumtoxinE) is not yet FDA-approved.

April 28, 2026

The FDA Just Fast-Tracked Three Psychedelic Drug Programs. Here’s What the Clinical Evidence Behind Them Actually Shows.

The essentials: On April 24, 2026, following an Executive Order signed by President Trump on April 18, the FDA announced a series of regulatory actions to accelerate development of psychedelic-based medicines for serious mental illness. Four distinct actions: (1) Three Commissioner’s National Priority Vouchers (CNPVs) issued to Compass Pathways (psilocybin/TRD), Usona Institute (psilocybin/MDD), and Transcend Therapeutics/Otsuka (methylone/PTSD). (2) The first U.S. clinical study of an ibogaine derivative (noribogaine, DemeRx NB) cleared to proceed. (3) Final guidance issued on clinical trial design for serotonin-2A agonists. (4) The overarching political context of an executive order directing HHS to accelerate access to treatments for depression, PTSD, and substance use disorders. None of these drugs are currently FDA-approved. This post focuses on what the clinical evidence actually shows for each program, where legitimate scientific promise lies, and what questions remain genuinely open.

Treatment-resistant depression affects an estimated 30% of people with major depressive disorder, roughly 100 million people globally who have tried multiple medications without adequate relief. PTSD affects 13 million Americans, and fewer than half respond adequately to available first-line treatments. These are large populations with severe unmet need, and they have been waiting for something meaningfully better for a long time.

On April 24, 2026, the FDA announced a series of regulatory actions to accelerate the development of psychedelic-based medicines, specifically serotonin-2A agonists and related compounds, for serious mental illness. Three companies received Commissioner’s National Priority Vouchers (CNPVs). An early-phase clinical study of a derivative of ibogaine was cleared to proceed. And final guidance on how to design clinical trials for this drug class was issued.

These actions followed an Executive Order signed by President Trump on April 18, directing HHS to accelerate access to treatments for serious mental illness, with explicit mention of psychedelic therapies and veterans. The political context is real and worth acknowledging, but it does not determine whether the underlying science is sound. This post focuses on what the evidence actually shows for each program, where the genuine clinical promise lies, and what legitimate scientific questions remain open.

What the FDA Actually Did on April 24

There are four distinct actions in the April 24 announcement, and they are not all equal in regulatory significance:

Action	What it means	What it does not mean
3 CNPVs issued (Compass, Usona, Transcend/Otsuka)	FDA review compressed to approximately 1 to 2 months after NDA submission, versus the standard 10 to 12 months	Not an approval; not an efficacy endorsement. The NDA must still be submitted and reviewed.
Noribogaine IND cleared (DemeRx NB)	First-ever U.S. clinical study of an ibogaine derivative can proceed. Phase 1 only.	The drug is not approved. Phase 1 tests safety and dosing in a small controlled sample.
Final guidance issued on serotonin-2A agonist trial design	Sponsors now have a definitive FDA framework for how to design psychedelic drug trials, addressing the unique scientific challenges of blinding and endpoints.	Does not lower the bar for evidence; specifies what is needed.
Executive Order context	Signals political priority and may increase resource allocation and FDA engagement speed	Does not change the legal standard for approval: substantial evidence of safety and efficacy

What is a Commissioner’s National Priority Voucher (CNPV)? The CNPV program was launched in 2025 as a way to compress the FDA review timeline for drugs designated as national health priorities. A CNPV compresses the FDA’s review to approximately 1 to 2 months from NDA submission, compared to the standard 10 to 12 months. Earlier in 2026, CNPVs were used to approve Foundayo (orforglipron, oral GLP-1 for obesity) in 50 days and Wegovy HD in 54 days. For psychedelic drugs, a CNPV does not mean the FDA has pre-approved the drug or concluded it works. It means the FDA will prioritize and accelerate its review once a complete application is submitted. The drugs still need to demonstrate substantial evidence of safety and efficacy through their NDA package. A company that submits an NDA and receives a CNPV could still receive a Complete Response Letter if the evidence is insufficient, as happened with MDMA/Lykos, which did not have a CNPV but illustrates the principle.

COMP360 (Compass Pathways): Two Phase 3 Trials, Both Positive

Of the three CNPV recipients, Compass Pathways has by far the most mature clinical evidence package. COMP360 is a synthetic, proprietary formulation of psilocybin, the active compound in psychoactive mushrooms, being developed for treatment-resistant depression (TRD), defined as inadequate response to at least two adequate courses of antidepressant therapy.

Compass has completed the primary endpoints of both Phase 3 trials in this program, and both are positive:

Trial	Design	Primary endpoint result
COMP005	Randomized, double-blind; single 25 mg dose vs. placebo; approximately 568 patients; North America and Europe	MADRS score difference at week 6: 3.6 points versus placebo (p less than 0.001). Highly statistically significant and clinically meaningful.
COMP006	Randomized, double-blind; two fixed doses (3 weeks apart) of 25 mg vs. 1 mg; approximately 568 patients	MADRS difference between 25 mg and 1 mg at week 6: 3.8 points (p less than 0.001). Durable effects; 26-week data expected Q3 2026.

The MADRS (Montgomery-Asberg Depression Rating Scale) is the most widely used validated scale for measuring depression severity in clinical trials. A difference of 3.6 to 3.8 points is considered clinically meaningful, particularly in a treatment-resistant population where previous antidepressants have failed. Across two robust Phase 3 trials involving more than 1,000 participants combined, COMP360 produced consistent, highly statistically significant results at the primary endpoint, a result that is notable in a population where proving benefit has historically been challenging.

Critically, the Data Safety Monitoring Board for the program reported no evidence of a clinically meaningful imbalance in suicidality between treatment and placebo arms in either COMP005 or COMP006, a reassuring finding for a drug used in a depressed population with elevated baseline suicide risk. The most common adverse events were headache, nausea, and visual hallucinations, the large majority occurring on the day of administration and resolving within 24 hours.

Compass has indicated it plans to submit an NDA to the FDA in Q4 2026. With a CNPV in hand, review could potentially be completed in early 2027.

Usona Institute: Psilocybin for Major Depressive Disorder

The Usona Institute is a Wisconsin-based nonprofit developing PSIL201, a psilocybin formulation for major depressive disorder (MDD) rather than treatment-resistant depression. The distinction matters: MDD is a broader population that includes patients for whom first-line antidepressants may have provided partial or inadequate response but who do not meet the stricter TRD definition.

Usona’s program received FDA Breakthrough Therapy designation in 2019, one of the earliest such designations for a psychedelic drug. It is currently in Phase 3. Phase 2 trial data showed rapid, sustained reductions in depressive symptoms in many participants, with benefits persisting at six months after a single session, a durability profile notably different from daily antidepressants, which require continuous dosing.

As a nonprofit, Usona’s structure is oriented around access and affordability rather than investor return. The CNPV accelerates its path to FDA review once Phase 3 data is complete.

Transcend Therapeutics / Otsuka: Methylone for PTSD

The third CNPV went to TSND-201, a methylone-based treatment for PTSD being developed by Transcend Therapeutics and in the process of being acquired by Otsuka. This is the most scientifically interesting and the most clinically immature of the three programs.

Methylone is a synthetic entactogen, a compound that produces empathogenic and prosocial effects, structurally related to MDMA but with a different pharmacological profile. It targets similar receptor systems (serotonin, dopamine, norepinephrine) but is thought to have reduced cardiovascular effects and a somewhat shorter duration of action than MDMA. Transcend received FDA Breakthrough Therapy designation for TSND-201 in July 2025.

TSND-201 met its primary endpoint in a Phase 2 study, showing significant improvement on the Clinician-Administered PTSD Scale (CAPS-5) compared to placebo, the same validated scale used in the MDMA/Lykos trials. The program is now entering Phase 3. A CNPV for a Phase 3-stage program is less immediately actionable than for a program preparing an NDA, but it signals FDA’s willingness to prioritize the review once Phase 3 data is available.

Why methylone and not MDMA? The Lykos rejection context The MDMA/PTSD story is the essential backdrop for understanding why methylone is receiving attention. Lykos Therapeutics spent years developing MDMA-assisted therapy for PTSD and submitted an NDA with Phase 3 data showing 71% of patients no longer met PTSD criteria after treatment (versus roughly 48% on placebo). The FDA rejected it in August 2024 and issued a Complete Response Letter. The FDA’s concerns with the Lykos application were multiple: questions about functional unblinding (MDMA’s subjective effects make it nearly impossible for patients to not know whether they received drug or placebo, potentially inflating self-reported outcomes); concerns about trial conduct integrity; and questions about the standardization of the psychotherapy component. An FDA advisory committee voted 10 to 1 that the benefits did not outweigh the risks. A retraction of several early Lykos trial papers compounded the credibility issues. Methylone enters this space as a structurally related compound that may offer similar therapeutic mechanisms with potentially cleaner trial methodology, if the blinding and conduct issues that plagued MDMA development can be avoided. The final guidance issued April 24 specifically addresses these challenges for the entire class.

Noribogaine: The First Ibogaine Derivative to Enter U.S. Clinical Trials

The most novel regulatory action in the April 24 announcement is the IND clearance for DemeRx NB to begin a Phase 1 clinical study of noribogaine hydrochloride for alcohol use disorder. The FDA described it as the first instance in which the agency has allowed a clinical study of a derivative of ibogaine in the United States.

What is ibogaine, and why the interest?

Ibogaine is a psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to West Central Africa. It has been used in ceremonial contexts by the Bwiti tradition for generations and has been studied for its potential to interrupt addiction, particularly opioid and alcohol dependence, through a mechanism quite different from psilocybin or MDMA. Ibogaine appears to act on multiple receptor systems simultaneously, including opioid receptors, NMDA receptors, serotonin transporters, and sigma receptors, and produces a prolonged, intense visionary experience often described as a life review.

The clinical interest in ibogaine for addiction is supported by observational data and case reports suggesting dramatic reductions in opioid withdrawal symptoms and prolonged periods of abstinence after a single treatment. Researchers at Stanford and elsewhere have documented cases of significant improvement in PTSD and traumatic brain injury symptoms following ibogaine treatment in settings outside the United States where it is legal.

Why noribogaine rather than ibogaine itself?

Ibogaine carries a serious safety concern that has prevented its clinical development in the U.S.: cardiac arrhythmia. Ibogaine blocks cardiac potassium channels (hERG), prolonging the QTc interval and creating a risk of potentially fatal ventricular arrhythmias. Several deaths have been reported in unregulated ibogaine treatment settings, attributed to this cardiac mechanism.

Noribogaine is ibogaine’s primary metabolite, the compound the body converts ibogaine into after administration. It retains many of ibogaine’s pharmacological properties but appears to have a reduced cardiac safety burden based on preclinical and early human data. DemeRx NB’s Phase 1 study will evaluate noribogaine’s safety, tolerability, and pharmacokinetics in a closely monitored clinical setting, the foundational data needed before any larger efficacy studies could proceed.

The FDA’s IND clearance is not an endorsement of efficacy. It means the agency has reviewed the preclinical safety package and determined it is adequate to proceed with first-in-human studies under controlled conditions. The noribogaine program is at the very beginning of the clinical development pathway.

The Final Guidance: Why Trial Design Is the Central Scientific Challenge

The fourth action, the issuance of final guidance on designing clinical trials for serotonin-2A agonists, is arguably the most durable of the four. It addresses the core methodological challenges that have haunted psychedelic clinical research for decades and that contributed directly to the Lykos rejection.

Psychedelic drugs create unique clinical trial design problems that do not apply to conventional pharmaceuticals:

Functional unblinding: Psychedelics produce unmistakable subjective effects. Participants almost invariably know whether they received the active drug or placebo, which can inflate self-reported outcomes through expectancy effects and therapeutic relationship dynamics. The guidance addresses this through active placebo comparators, pre-specified blinding assessment, and outcome measure selection.

The psychotherapy component: Most psychedelic treatment protocols pair drug administration with structured psychotherapy sessions, including preparation, dosing, and integration. How to standardize, manualize, and report this component so that an approved therapy is reproducible in clinical practice has been a major regulatory challenge. The guidance provides foundational recommendations.

Session monitoring requirements: These are not drugs you take at home. Administration occurs in monitored clinical settings, often all-day sessions with trained therapists present. The logistics of adequate monitoring, adverse event capture, and patient safety require specific infrastructure specifications.

Outcome measure selection: Traditional depression and PTSD rating scales were not designed to capture the kind of rapid, potentially lasting shifts in symptomatology that psychedelic therapies may produce. The guidance addresses which endpoints are acceptable for demonstrating clinical benefit.

This guidance having moved from draft to final, incorporating public comment, means that sponsors now have a definitive framework rather than interpretable draft recommendations. For companies preparing NDAs, this reduces regulatory uncertainty and should make clinical trial design decisions more defensible.

Reading This Evenhandedly: What This Signals and What It Does Not

The psychedelic medicine space has attracted both credible science and significant hype, and the April 24 announcement has elements of both. An honest assessment requires holding both simultaneously.

What the evidence legitimately supports

The Compass psilocybin program for TRD has now produced two positive Phase 3 trials with consistent, statistically significant, and clinically meaningful results. This is real evidence of a real effect in a population where existing treatments have genuinely failed. The Usona Phase 2 MDD data is encouraging. The DSMB’s finding of no meaningful imbalance in suicidality in either Compass trial is reassuring for the safety profile.

These drugs work through a distinctive mechanism: psilocybin is converted in the body to psilocin, which acts as an agonist at serotonin-2A receptors densely expressed in cortical regions. The result is a temporary but profound disruption of the default mode network, the brain’s self-referential processing hub, which is hyperactive in depression and PTSD. There is a growing body of neuroimaging and mechanistic research supporting this model.

What remains genuinely uncertain

Long-term durability: How long do the benefits last after a 1 to 2 dose treatment? The 26-week COMP006 data, expected Q3 2026, will be the first rigorous window into this question for TRD. Phase 2 psilocybin data has shown benefits at 3 to 6 months; whether this holds at 1 to 2 years is not yet known from controlled trials.

The blinding problem: Functional unblinding remains the most serious methodological challenge for the class. Even with the new guidance, the question of how much of the observed effect is genuine pharmacology versus expectancy and therapeutic relationship is not fully resolved. The 1 mg active comparator dose in the Compass trials is an attempt to address this, but it remains a subject of legitimate scientific debate.

Scalability: Psychedelic-assisted therapy as currently practiced requires significant infrastructure: trained therapists, all-day monitoring sessions, preparation and integration support. How this translates into real-world healthcare delivery, at what cost, and with what fidelity to trial protocols is an open question with major access implications.

The political acceleration: The executive order framing, particularly the emphasis on veterans and ibogaine specifically, reflects lobbying by specific interest groups. Political enthusiasm for a treatment does not validate or invalidate its science, but the concentration of federal attention on specific compounds driven partly by political rather than purely scientific prioritization is worth tracking as the field moves forward.

In the April 24 announcement, FDA Commissioner Marty Makary, MD, MPH stated that as this field moves forward, it is critical that drug development be grounded in sound science and rigorous clinical evidence, describing this standard as what the nation’s veterans and all Americans suffering from these conditions deserve. The standard he named, substantial evidence of safety and efficacy through rigorous clinical trials, is the one against which the approvals that follow will be judged. The CNPV accelerates the clock; it does not change the threshold.

Are you following the psychedelic medicine pipeline as a patient, clinician, or researcher?

The treatment-resistant depression and PTSD populations represent tens of millions of people for whom existing treatments have provided inadequate relief. If the Compass NDA, backed by two positive Phase 3 trials, results in an approved drug in 2027, it will be a genuine clinical advance for a population that has been waiting a long time. The noribogaine program is further out but scientifically interesting. The methylone/PTSD program sits in a space where the need is enormous and the precedent from MDMA’s rejection is recent and instructive.

For patients with treatment-resistant depression or PTSD interested in the clinical trial landscape, ClinicalTrials.gov is the most current source for open enrollment studies. The Multidisciplinary Association for Psychedelic Studies (MAPS) and Compass Pathways both maintain current information on trial availability. For general mental health resources, the National Alliance on Mental Illness (NAMI) and the 988 Suicide and Crisis Lifeline (call or text 988) are available 24 hours a day. We will continue tracking this space as the Compass NDA submission and the COMP006 26-week data approach.

Sources

FDA press announcement: FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order. April 24, 2026. fda.gov

Executive Order: White House. Accelerating Medical Treatments for Serious Mental Illness. April 18, 2026. whitehouse.gov

FDA final guidance: Clinical Trials of Serotonin-2A Agonists for the Development of Mental Health-Related Indications: Guidance for Industry. FDA.gov. April 2026.

CNPV recipients: Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push. Fierce Biotech. April 2026.

CNN coverage: FDA moves to fast-track review of psilocybin and methylone for mental health. CNN. April 24, 2026.

Psychedelic Alpha: Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona. psychedelicalpha.com. April 24, 2026.

NBC News: FDA grants quick review for 3 psychedelic drug trials. nbcnews.com. April 24, 2026.

COMP005 Phase 3 results: Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for TRD. ir.compasspathways.com. June 23, 2025.

COMP006 Phase 3 results: Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360. ir.compasspathways.com. February 17, 2026.

Psychiatric Times: COMP360 Psilocybin for Treatment-Resistant Depression Achieves Primary Endpoint in Phase 3 Trial. psychiatrictimes.com. February 2026.

MDMA/Lykos rejection (NPR): FDA rejects MDMA, disappointing drugmaker Lykos and psychedelics industry. npr.org. August 9, 2024.

Lykos CRL context (STAT News): FDA criticism of MDMA-assisted therapy is an opportunity for psychedelic medicine. STAT News. October 2025.

MAPS statement: MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy. maps.org. September 4, 2025.

Stanford ibogaine study: Ibogaine Treatment Outcomes for Veterans. Stanford Medicine. 2023.

Disclaimer: Health Evidence Digest provides general information about FDA regulatory updates and health research for educational purposes. This content is not a substitute for professional medical advice. None of the drugs discussed in this post — psilocybin (COMP360, PSIL201), methylone (TSND-201), or noribogaine — are currently FDA-approved treatments. If you are experiencing symptoms of depression, PTSD, or another mental health condition, please consult a qualified healthcare provider. Crisis support is available 24/7 by calling or texting 988.

April 27, 2026

The First Gene Therapy for Deafness Is Here and It’s Free. Here’s What That Actually Means.

The essentials: On April 23, 2026, the FDA approved Otarmeni (lunsotogene parvec-cwha, Regeneron) as the first FDA-approved gene therapy for inherited deafness in history. The therapy is indicated for children and adults with profound hearing loss due to biallelic mutations in the OTOF gene, which causes a condition where the inner ear is structurally normal but cannot transmit sound signals to the brain. The clinical basis: Results from the CHORD Phase 1/2 trial (NCT05295056) showing 80% of participants (16 of 20) achieved or exceeded the primary endpoint at 6 months, and 42% of participants with longer follow-up achieved normal hearing. Nine of 12 children who received the therapy gained enough hearing to stop using cochlear implants. The approval was granted under accelerated approval with continued approval contingent on confirmatory trial results. This was also the first gene therapy approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) program, approved in just 61 days after BLA submission. The price: Regeneron has stated it will provide Otarmeni at no cost for the drug itself to eligible patients in the United States. Important caveat: the surgical procedure required to administer it is not covered by Regeneron and will be subject to normal insurance and cost-sharing.

When Travis Smith was born, he failed his newborn hearing test. His mother, Sierra, was told it was probably just fluid in the ears. But weeks passed, and nothing changed. Slamming pots and pans, yelling his name — nothing reached him. Travis was, as Sierra later described it, 100% deaf.

A few months later, after genetic testing confirmed a mutation in a gene called OTOF, Travis received an experimental treatment at Columbia University in New York. About ten weeks after the procedure, Sierra laughed loudly while driving. Travis, asleep in his car seat, startled for the first time. She and her friend started yelling. He woke up.

On April 23, 2026, that experimental treatment became Otarmeni (lunsotogene parvec-cwha), the first FDA-approved gene therapy for inherited deafness in history. And in a move that surprised nearly everyone in the pharmaceutical industry, Regeneron announced it will provide the drug at no cost to eligible patients in the United States.

There is a lot to unpack here: the science, the price, the very reasonable counterarguments from the Deaf community, and what this means for the larger field of genetic hearing loss.

What Is OTOF-Related Hearing Loss?

Hearing happens through a remarkably precise chain of events. Sound waves enter the ear canal, cause the eardrum to vibrate, and those vibrations travel through three tiny bones in the middle ear before reaching the cochlea, the snail-shaped structure of the inner ear. Inside the cochlea, thousands of hair cells convert those vibrations into electrical signals. A protein called otoferlin is what allows those hair cells to release the neurotransmitters that carry those signals to the auditory nerve and then on to the brain.

In children with biallelic mutations in the OTOF gene, meaning they inherited a non-working copy from both parents, otoferlin is absent or non-functional. The cochlea is structurally intact. The hair cells are there. Sound waves are converted normally. But the signal cannot be passed to the brain because the neurotransmitter release mechanism is broken. The result is profound sensorineural deafness from birth, despite an otherwise normal-looking inner ear.

OTOF mutations account for roughly 2% to 8% of inherited non-syndromic hearing loss, according to the FDA. In absolute numbers, about 50 babies are born each year in the United States with the condition, a number small enough that most audiologists and pediatricians will rarely encounter it. But the impact on those families is total..

How Otarmeni Works

Otarmeni is an adeno-associated virus (AAV) vector-based gene therapy, specifically a dual-vector system, because the OTOF gene is unusually large and too big to fit inside a single AAV. Regeneron’s approach splits the gene in half across two AAV serotype 1 vectors that are co-administered. Once inside the hair cells, the two halves recombine to produce a functional OTOF gene, which then directs the cells to make working otoferlin protein.

The treatment is administered surgically. Under general anesthesia, a surgeon makes a small incision behind the ear to access the cochlea and delivers the viral vectors directly into the fluid-filled space of the inner ear via a syringe and catheter, a procedure similar in approach to cochlear implant surgery, though the anatomy targeted is slightly different. The therapy can be given to one ear or both.

One important technical detail: the OTOF gene in Otarmeni is under the control of a proprietary Myo15 promoter, which is designed to restrict gene expression specifically to hair cells that normally produce otoferlin. This cell-type specificity is important both for efficacy and safety, as it reduces the chance of off-target expression in tissues that do not need the protein.

Why is the OTOF gene so large, and why does that matter? Standard single-AAV gene therapies are limited by the packaging capacity of the virus, roughly 4.7 kilobases of genetic material. The OTOF gene is approximately 6 kilobases, which has long made it technically challenging to deliver in a single vector. Regeneron’s dual-AAV approach is one of several strategies the field has developed to work around this constraint. It addresses the same large-gene delivery challenge that has been encountered in gene therapy for conditions like Duchenne muscular dystrophy. The fact that this approach produced consistent, durable results in the CHORD trial is a meaningful technical achievement, not just for hearing loss, but for the broader field of large-gene delivery.

The CHORD Trial: What the Clinical Data Shows

The FDA approval is based on results from the CHORD trial (NCT05295056), an ongoing, registrational Phase 1/2 multicenter, open-label study. Twenty participants aged 10 months to 16 years with molecularly confirmed OTOF mutations received a single dose of Otarmeni in one or both ears. The primary endpoint was improvement in hearing sensitivity measured by pure-tone audiometry at week 24.

CHORD trial key results
Participants meeting or exceeding primary endpoint at 6 months	16 of 20 (80%)
Participants achieving normal hearing with longer follow-up	42%
Children who stopped using cochlear implants after treatment	9 of 12
Minimum follow-up with durable hearing benefits	At least 2 years
Age range in trial	10 months to 16 years
Effect of age at treatment on efficacy	Not significant, which supported label inclusion of adults
Most common adverse events	Middle ear infection or inflammation, vomiting, nausea, dizziness (consistent with surgical procedure)

Source: CHORD Phase 1/2 trial, NCT05295056. Primary results published in NEJM, 2026.

Accelerated approval: what it means here Otarmeni received accelerated approval based on improvement in pure-tone audiometry as a surrogate endpoint. Continued approval may be contingent upon verification of treatment effects on clinical measures of speech development and quality of life, the outcomes families ultimately care most about. The confirmatory portion of the CHORD trial is ongoing. The FDA specifically notes that durability of hearing improvement is a key variable still being assessed. For a one-time gene therapy, how long the benefit lasts is the central question that will define long-term clinical value and public health cost-effectiveness. The approval was also notably fast: granted just 61 days after the Biologics License Application was filed, tied for the fastest BLA approval in modern FDA history, and the first gene therapy approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) program. For context on how the CNPV program works and which other drug programs have received vouchers, see our post on the FDA’s fast-tracking of three psychedelic drug programs.

The Price Tag: $0. What Is Actually Going On There?

Gene therapies for rare diseases are expensive. Not slightly expensive — the kind of expensive that regularly makes headlines. Hemgenix (hemophilia B) was priced at $3.5 million per patient. Zolgensma (spinal muscular atrophy) at $2.1 million. Casgevy (sickle cell disease) at $2.2 million. These prices reflect the reality of developing treatments for patient populations sometimes numbering in the hundreds, where there is no scale to amortize development costs.

Regeneron’s internal analysis suggested Otarmeni could have been priced as high as $4 million per patient, generating an estimated $200 million to $400 million in annual revenue. The company chose not to. Regeneron’s co-founder and president, Dr. George Yancopoulos, acknowledged the company made a deliberate choice to prioritize access over revenue from this particular therapy, despite internal discussion about alternative pricing models.

That decision came alongside Regeneron’s participation in the Trump administration’s Most Favored Nation drug pricing announcement, a policy effort to bring U.S. drug prices more in line with prices paid in European and Asian markets. The timing was politically convenient, but the substance of offering the therapy free stands regardless of the surrounding context.

Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER), noted in a statement following the approval that Regeneron has shown that one option companies can consider to ensure affordable patient access to these therapies is to simply not charge the health system for the drug. She called it a model worth understanding for what it demonstrates about the range of approaches available to developers of rare disease therapies.

There are important nuances in the “free” framing worth noting clearly. Regeneron is providing the drug itself at no cost to clinically eligible patients. The company does not control and is not covering the cost of the surgical procedure required to administer it. Cochlear implant surgery, which uses a similar approach, typically costs between $30,000 and $100,000 including hospitalization and anesthesia. The out-of-pocket portion for patients will depend on their insurance coverage for the procedure, not the drug.

Otarmeni’s pricing model also has no established precedent for international markets. CEO Leonard Schleifer told CNBC that overseas pricing has not been set, stating that other countries should pay their fair share. For families outside the United States with children who have OTOF mutations, the picture is much less clear.

A Perspective Worth Sitting With: The Deaf Community Response

Not everyone greeted this approval with unqualified celebration, and that response deserves more than a footnote.

Jaipreet Virdi, a historian of medicine, technology, and deafness at the University of Victoria who is herself deaf, raised a concern that has been articulated within Deaf culture for years: that genetic therapies targeting deafness can reinforce the assumption that deafness is a deficiency to be corrected rather than a difference to be accommodated. For members of the Deaf community who use sign language, have Deaf cultural identities, and live full, rich lives, a medical framing of deafness as a problem in need of eradication is not a neutral position.

This is not a fringe view. It is a well-established strand of Deaf cultural identity that preceded cochlear implants and will continue to evolve as genetic therapies expand. It does not invalidate what Otarmeni has done for Travis, or Miles, or the other children in the CHORD trial. But it does mean that the conversation around who benefits from these therapies, and on what terms, is more complex than the headline numbers suggest.

Regeneron’s own press release acknowledged this directly. Janet DesGeorges, Executive Director of Hands and Voices, a family-driven organization supporting children with all forms of hearing loss and all communication approaches, was quoted in the approval announcement noting that families deserve access to balanced information and a range of options when navigating genetic hearing loss, and that the choice of approach belongs to individual families.

Cochlear implants versus gene therapy: how they are different Cochlear implants are electronic devices surgically implanted in the inner ear that bypass damaged hair cells and directly stimulate the auditory nerve. They restore useful hearing for many patients but do not restore physiological hearing. The sound quality is different from natural hearing and varies considerably between users. They require external processors worn behind the ear, run on batteries, and must be managed over a lifetime. Otarmeni, by contrast, restores the biological mechanism of hearing by enabling the hair cells themselves to function. The hearing it produces is closer to natural hearing that is present continuously without external hardware. However, it only works for patients with OTOF mutations who have no prior cochlear implant in the ear to be treated. The two approaches are not directly comparable and serve partially overlapping but distinct populations.

Beyond OTOF: What This Approval Unlocks

OTOF mutations account for only 1% to 3% of cases of genetic hearing loss at birth. The significance of this approval is therefore less about its immediate patient population, roughly 50 children per year in the U.S., and more about what it proves and where it leads.

Genetic hearing loss involves more than 100 identified genes. OTOF attracted early attention because its mechanism was well-understood, the hair cell pathology is isolated (outer hair cell function is preserved), and the AAV delivery route to the cochlea had been mapped in preclinical models. Proving that this approach works, that you can deliver a gene to inner ear hair cells via surgical infusion and produce durable, functional hearing, is the foundational result the broader field needed.

Eli Lilly and several academic groups are also developing gene therapies targeting OTOF, many showing comparably strong results. The publication of strong data in the New England Journal of Medicine in 2026, which preceded and contributed to the FDA’s accelerated review, has drawn significant investment into the broader genetic hearing loss space. Dr. Lawrence Lustig of Columbia University, who treated several CHORD participants, noted substantial interest in pursuing other forms of genetic deafness that are more common, and that investment is now arriving.

Researchers are also beginning to consider whether someday gene therapy approaches might address acquired hearing loss from aging or noise exposure, which affects hundreds of millions of people globally. That is a much longer road, requiring different targets and delivery methods. But the clinical validation of cochlear gene delivery in OTOF patients makes it a more credibly walkable path than it was before April 23, 2026.

What This Approval Does Not Yet Answer

How long does the benefit last?

The CHORD trial has follow-up of at least two years in some participants, and hearing benefits have been durable over that period. But two years is a short window for what is being offered as a one-time, potentially permanent treatment, particularly for children who may live for seven more decades. Long-term follow-up from the confirmatory CHORD trial will be critical. The FDA has specifically listed durability of hearing improvement as a condition of continued approval.

What about speech and language development?

Pure-tone audiometry tells us whether a patient can detect sounds at various frequencies and volumes. It does not directly measure what matters most to families: speech comprehension, language acquisition, and the ability to communicate in the ways they choose. The confirmatory trial is tasked with verifying treatment effects on these clinical measures. The gap between “can detect a whisper” and “is developing speech and language normally” is the one families and clinicians most need filled.

Which patients are candidates?

The indication requires molecularly confirmed biallelic OTOF variants, preserved outer hair cell function (confirmed by otoacoustic emissions testing), and no prior cochlear implant in the ear to be treated. Genetic testing infrastructure for identifying OTOF mutations in newborns varies considerably across health systems. The therapy’s real-world reach will depend partly on how systematically genetic diagnosis of congenital deafness is pursued, which is currently inconsistent in the U.S.

For families navigating genetic hearing loss:

This approval touches on intersecting questions: the science of gene delivery, the ethics of treating deafness, the unprecedented pricing decision, and what proof-of-concept in OTOF means for the dozens of other genetic causes of hearing loss. For families with children recently diagnosed with genetic hearing loss, regardless of which gene is involved, several organizations maintain current resources:

Hands and Voices supports families navigating all communication approaches without advocacy for any single one. The National Association of the Deaf (NAD) provides resources from a Deaf cultural perspective. The Hearing Loss Association of America (HLAA) offers advocacy and practical support resources. The NIDCD maintains clinical information on cochlear implants and emerging therapies. Families interested in the CHORD confirmatory trial or other OTOF gene therapy studies can search for open enrollment studies at ClinicalTrials.gov.

Sources

FDA approval announcement: FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program. FDA.gov. April 23, 2026.

Regeneron press release: Otarmeni (lunsotogene parvec-cwha) Approved by FDA. investor.regeneron.com. April 23, 2026.

CHORD trial registration: NCT05295056. ClinicalTrials.gov.

Primary clinical data: CHORD Phase 1/2 trial results. New England Journal of Medicine. 2026.

ICER pricing commentary: Institute for Clinical and Economic Review. Statement on Otarmeni pricing. icer.org.

Pricing context (CNBC): Schleifer L. Regeneron weighs overseas price for Otarmeni. CNBC. April 24, 2026.

Deaf community perspective: Virdi J. Quoted in NPR/KERA News. Rob Stein. The FDA gives the green light to the first gene therapy for deafness. keranews.org. April 23, 2026.

Hands and Voices: handsandvoices.org. Cited in Regeneron approval press release.

Patient story (Travis): NPR/KERA News. Rob Stein. April 23, 2026.

Patient story (Miles): CNN. Meg Tirrell. April 23, 2026.

Pipeline context: Gene therapy for deafness approved. Science. April 23, 2026.

Patient and family resources: Hands and Voices | National Association of the Deaf | Hearing Loss Association of America | NIDCD Cochlear Implants | ClinicalTrials.gov: OTOF hearing loss

Disclaimer: Health Evidence Digest provides general information about health research and FDA decisions for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Accelerated approval does not constitute final confirmation of clinical benefit. The confirmatory CHORD trial is ongoing. Always consult a qualified audiologist, otolaryngologist, or geneticist regarding treatment decisions for your child or yourself.

April 26, 2026

Hands. Grip. Independence. What the FDA’s Clearance of the ExaStim® System Actually Means for Spinal Cord Injury Rehab.

📌 The essentials On April 16, 2026, the FDA cleared the ExaStim Stimulation System (ANEUVO) for use in the United States, marking the first FDA-cleared transcutaneous spinal cord stimulation device for home use in adults with incomplete spinal cord injury. Important terminology: this is an FDA 510(k) clearance, not a drug approval. The distinction matters and is explained below. What ExaStim is cleared for: improving hand sensation and strength in adults aged 18 to 75 with chronic, non-progressive neurological deficits resulting from incomplete spinal cord injury, when used in conjunction with functional task practice. Where it can be used: both clinical settings and at home, under a prescribing clinician’s supervision. The regulatory basis: ExaStim received FDA Breakthrough Device Designation, completed the ASPIRE clinical study at the Kennedy Krieger Institute and other sites, and received CE Mark certification in Europe in April 2025 before U.S. clearance. The broader context: ExaStim is entering a real but still-developing evidence base for transcutaneous spinal cord stimulation. What the clinical data shows, where it is strongest, and where legitimate gaps remain is what this post covers.

Spinal cord injury (SCI) affects approximately 18,000 Americans each year and an estimated 302,000 people currently live with SCI in the United States. The consequences are not uniform. About 69% of new SCI cases are classified as incomplete, meaning some neural pathways across the injury site are preserved, and some degree of function below the level of injury remains possible. For people with cervical incomplete SCI specifically, the loss of hand and arm function is consistently ranked as the highest priority for recovery, above walking. Being able to hold a cup. Press a button. Open a door independently. These are not small things.

The standard rehabilitation toolkit for incomplete SCI, including physical therapy, occupational therapy, and conventional functional electrical stimulation, produces meaningful but limited gains for many patients. A growing body of research has been investigating whether non-invasive electrical stimulation of the spinal cord itself, delivered through electrodes placed on the skin rather than surgically implanted, can amplify the nervous system’s own residual capacity for recovery.

The FDA’s April 16 clearance of the ExaStim Stimulation System from ANEUVO represents the first time a transcutaneous spinal cord stimulation device has been cleared specifically for at-home use in incomplete SCI in the United States. This post covers what the device is, how it works, what the clinical evidence actually shows about transcutaneous spinal stimulation as a treatment class, what the ASPIRE study contributed, and what this clearance does and does not mean for patients navigating SCI rehabilitation.

What Is Transcutaneous Spinal Cord Stimulation and Why Is It Relevant to SCI?

To understand what ExaStim does, it helps to understand what happens at the neuromuscular level in incomplete spinal cord injury and why spinal stimulation might influence it.

The injured spinal cord is not simply broken

In a complete SCI, the neural pathways crossing the injury site are entirely severed, and no voluntary signal from the brain reaches muscles below the injury. In an incomplete SCI, some pathways remain partially intact. But “partially intact” does not mean “working normally.” The surviving connections often cannot generate sufficient neural drive on their own to produce coordinated voluntary movement. The circuits exist, but they are not generating enough signal to translate into function.

Neuroplasticity, the nervous system’s capacity to reorganize and strengthen connections through activity-based learning, is a central principle of SCI rehabilitation. The more consistently neural circuits are activated, the more the nervous system can reinforce and strengthen those connections over time. This is why task-specific training, where you practice the actual functional movement you are trying to recover, tends to outperform generalized exercise in SCI rehabilitation.

Transcutaneous spinal cord stimulation (tSCS) delivers low-level electrical current through electrodes placed on the skin over the spinal cord, at the level corresponding to the neural circuits being targeted. For upper extremity function in cervical SCI, electrodes are typically placed at the cervical spinal level, approximately C4 to C7. The proposed mechanism is that tSCS increases the excitability of surviving neural pathways and the motor neuron pools they connect to, making it easier for the brain’s residual descending signals to produce muscle activity. In effect, it lowers the threshold for the injured circuits to fire, potentially unlocking function that exists but cannot be accessed without facilitation.

What distinguishes ExaStim within the tSCS category

ExaStim uses a multi-electrode array rather than the single-pair electrode configurations used in earlier-generation tSCS research. This matters because different muscle groups in the arm and hand are controlled by different spinal cord segments and fiber pathways. A multi-electrode system allows the stimulation to be spatially targeted and the parameters personalized to an individual patient’s injury level, neurological profile, and therapy goals, rather than delivering a single undifferentiated current across the whole area. The system is controlled via a mobile digital device, enabling flexible parameter adjustment in clinical and home settings.

ExaStim received FDA Breakthrough Device Designation, a designation reserved for devices that provide more effective treatment or diagnosis of a serious condition compared to available options and where no approved alternative exists. This designation preceded the FDA clearance and provided an expedited review pathway.

The Regulatory Distinction: Clearance Versus Approval

The original post on this site described ExaStim as “approved,” which is not technically accurate and is worth correcting explicitly. This distinction matters on a health evidence site.

FDA clearance (510(k)) means the FDA has determined that a device is substantially equivalent to a legally marketed predicate device in terms of its intended use and technological characteristics. It is the standard pathway for medical devices. The clearance process does not require the same level of randomized controlled trial evidence as a drug approval. It requires demonstration of safety and effectiveness sufficient to establish substantial equivalence.

FDA approval (PMA or BLA) is the more rigorous pathway used for higher-risk devices or drugs, requiring independent demonstration of safety and effectiveness through controlled clinical trials.

ExaStim was cleared through the 510(k) pathway. This is normal and appropriate for this category of device. It does not mean the device lacks evidence. It means the evidence standard is different from what would be required for a drug approval. The distinction is important for patients and clinicians evaluating the strength of the regulatory basis.

What the Evidence Shows: The Broader tSCS Literature

ExaStim’s clearance builds on a growing but still-developing body of research on transcutaneous spinal cord stimulation for SCI. The most important thing to understand about this evidence base is where it is genuinely strong and where gaps remain.

What the peer-reviewed literature shows

A 2024 meta-analysis published in Neurorehabilitation and Neural Repair pooled results from six randomized controlled trials of transcutaneous spinal cord stimulation in SCI patients. The analysis found that tSCS combined with conventional rehabilitation significantly improved limb strength (mean difference 4.82, p=0.004) and reduced spasticity (MD 0.40, p=0.02) compared to conventional rehabilitation alone. Walking speed and distance also improved significantly. The upper-extremity motor function composite endpoint did not reach statistical significance in this specific pooled analysis (p=0.75), though individual studies have shown gains in grip strength and hand function.

A 2024 review published in the Journal of Neurotrauma examining transcutaneous stimulation specifically for upper extremity function in cervical SCI reviewed studies involving 55 participants across multiple research groups. The review found that tSCS combined with task-specific training “consistently improved voluntary control of arm and hand function and sensation,” though noting the studies were limited in number and sample size.

A 2026 systematic review in Life covering cervical spinal cord stimulation through July 2025, including epidural, intraspinal, and transcutaneous approaches, synthesized preclinical and clinical evidence and found consistent evidence of functional improvement across approaches, while noting substantial heterogeneity across study designs that precluded meta-analysis of the combined dataset.

A systematic review in PMC covering electrical stimulation modalities for motor recovery in SCI synthesized 37 clinical trials and found consistent evidence of functional improvement, with transcutaneous approaches showing promise as a non-invasive alternative to epidural stimulation.

What the evidence supports and what it does not yet confirm The evidence for transcutaneous spinal cord stimulation in incomplete SCI supports the following conclusions: tSCS combined with task-specific training improves motor neuron excitability and can augment voluntary movement in incomplete SCI. Limb strength and spasticity improvements are the most consistently demonstrated outcomes across RCTs. Hand and upper extremity function improvements have been shown in multiple studies, though the evidence base here is smaller and more heterogeneous than for lower extremity outcomes. The technology is safe and well-tolerated based on available data, with no major safety signals identified across the clinical trial literature. What the evidence does not yet confirm: long-term durability of functional gains after treatment ends, optimal stimulation parameters (frequency, intensity, electrode placement) for different injury levels and patient profiles, whether benefits generalize across the full spectrum of incomplete SCI severity, and how ExaStim’s specific multi-electrode platform compares to single-electrode systems used in most published research. These are legitimate open questions that the post-clearance clinical data and the ASPIRE long-term follow-up will need to address.

The ASPIRE Study: ANEUVO’s Foundational Clinical Evidence

The ASPIRE (Assessing non-invasive spinal Stimulation and PT/OT for motor Improvement Response with ExaStim) study was ANEUVO’s registrational clinical program, conducted at the International Center for Spinal Cord Injury at Kennedy Krieger Institute, affiliated with Johns Hopkins University School of Medicine, and at additional sites across the United States.

The study enrolled adults with upper extremity paralysis due to chronic, traumatic incomplete SCI. Participants received ExaStim tSCS therapy in combination with traditional physical and occupational therapy (PT/OT) rehabilitation as an adjunct treatment. The FDA designated the study as non-significant risk (NSR), meaning the agency determined that the risk profile did not warrant the oversight requirements applied to significant-risk device studies.

ANEUVO completed the ASPIRE study and has stated that results will be shared in early 2026. The full peer-reviewed publication of ASPIRE data has not yet been publicly available at the time of this post. The clearance was supported by the ASPIRE dataset alongside the preceding pilot study and the broader tSCS literature.

The pilot study that preceded ASPIRE, published in the Archives of Physical Medicine and Rehabilitation in 2023, evaluated ExaStim in a small group of participants with incomplete SCI and found preliminary evidence of treatment safety and possible effectiveness in improving upper limb function. The authors, who included both ANEUVO employees and independently funded investigators, noted that further investigation in a larger trial was warranted, which the ASPIRE study was designed to provide.

Important disclosure context: Several investigators in the ExaStim research program, including the ASPIRE principal investigator Dr. Rebecca Martin and others, received research funding from ANEUVO. Dr. Yi-Kai Lo and Rachel Yung are ANEUVO employees. This does not invalidate the research, but it is relevant context for interpreting company-funded data pending independent replication.

What FDA Clearance for Home Use Means in Practice

The clearance of ExaStim for both clinical and at-home use is notable. Most rehabilitation neurostimulation devices are limited to clinical or supervised settings. ExaStim’s home-use clearance means that once prescribed by a clinician, patients can continue therapy in their own home environment, extending the treatment dose beyond what clinic visits alone allow.

This matters because neuroplasticity-based rehabilitation for SCI appears to be dose-dependent: more frequent, consistent activation of the target neural circuits tends to produce better outcomes. Clinic-only therapy typically means two to three sessions per week. Home use could mean daily therapy, compressing the treatment timeline and potentially improving outcomes.

The practical requirements for home use include:

The device must be prescribed by a qualified clinician
Initial setup, parameter programming, and training occur in a clinical setting
Patients must be trained on electrode placement, device operation, and recognition of adverse effects
Ongoing clinical oversight continues throughout the home therapy period
The therapy is used in conjunction with functional task practice, not as a standalone intervention

The home-use clearance also has implications for access. Clinic-based rehabilitation is limited by geography, transportation, and appointment availability. For patients in rural or underserved areas, a home-based tSCS system potentially removes a significant logistical barrier to consistent rehabilitation. Whether insurance coverage follows the clearance is a separate and clinically important question. Home medical device coverage under Medicare, Medicaid, and private insurance for novel neuromodulation systems varies and requires prior authorization. Clinicians prescribing ExaStim should be prepared to support patients through the coverage determination process.

Where ExaStim Fits in the SCI Rehabilitation Landscape

Spinal cord injury rehabilitation encompasses a wide range of interventions. Here is where transcutaneous spinal cord stimulation, and ExaStim specifically, sits relative to other approaches:

Approach	How it works	FDA status	Evidence level
Physical and occupational therapy	Task-specific training, strength, and function	Standard of care, no device clearance needed	Strong; foundational
Functional electrical stimulation (FES)	Stimulates peripheral nerves/muscles directly to produce movement	Multiple FDA-cleared devices exist	Established; strongest for lower extremity
Epidural spinal cord stimulation	Surgically implanted electrodes deliver continuous or patterned stimulation to dorsal spinal cord	FDA cleared/approved for pain; investigational for SCI motor function	Growing; invasive
Transcutaneous spinal cord stimulation (tSCS)	Non-invasive surface electrodes deliver stimulation to spinal cord	ExaStim now FDA-cleared for incomplete SCI upper extremity	Emerging; consistent signals, limited large RCTs
Robotic exoskeletons	Mechanically assisted movement training	Multiple FDA-cleared devices	Established for gait training

ExaStim is positioned as an adjunct to, not a replacement for, physical and occupational therapy. The clearance language requires its use “in conjunction with functional task practice,” which is consistent with how tSCS has been used across the clinical trial literature and with the neuroplasticity rationale for the therapy.

What This Means for Patients and Clinicians

For patients with incomplete cervical SCI and their families

The ExaStim clearance represents a genuine expansion of the non-invasive rehabilitation toolkit. The device is the first of its kind cleared for home use in the United States, and the clinical evidence for tSCS as a class supports cautious optimism for upper extremity functional gains when combined with task-specific therapy.

What to realistically expect: ExaStim is a rehabilitation adjunct. It is designed to improve outcomes when used alongside physical and occupational therapy, not to produce dramatic recovery on its own. The evidence base shows meaningful improvements in grip strength and upper extremity function in incomplete SCI patients, with a good safety profile. The magnitude and durability of individual outcomes will vary.

What to discuss with your rehabilitation team: whether the degree of incompleteness and level of your injury makes you a candidate for upper extremity tSCS therapy; how ExaStim compares to other FES and neurostimulation devices your team has experience with; what the coverage situation is for your specific insurance; and how home-based ExaStim therapy would be integrated with your current PT/OT program.

The Christopher and Dana Reeve Foundation and the United Spinal Association both maintain current, clinician-reviewed resources on rehabilitation options for SCI. The Model Systems Knowledge Translation Center at the University of Washington maintains evidence-based SCI rehabilitation guides for patients and families. Clinical trials evaluating transcutaneous spinal cord stimulation can be found at ClinicalTrials.gov.

For rehabilitation clinicians

ExaStim’s clearance for home use creates a new prescribing and follow-up responsibility. The device integrates with a mobile platform for parameter management. ANEUVO is building out its clinical partnership program, and training and onboarding support is available through the company. Given that the ASPIRE full dataset has not yet been peer-reviewed and published, clinicians should follow the literature for independent replication of the company-funded results as they become available.

The tSCS class as a whole has a favorable safety profile across the published literature. The main clinical considerations for patient selection are injury completeness level (incomplete is required; complete injury is outside the cleared indication), chronicity of injury, and upper extremity functional baseline. Patients with implanted electronic devices (pacemakers, deep brain stimulators) are generally not candidates for transcutaneous spinal stimulation.

Sources

ANEUVO FDA clearance press release: ANEUVO Receives FDA Clearance for ExaStim Stimulation System. GlobeNewswire. April 16, 2026.

ASPIRE clinical study registration: NCT05294237. ClinicalTrials.gov.

ExaStim pilot study: Lo YK et al. A Pilot Study Using ExaStim to Restore Upper Limb Function After Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation. 2023.

2024 tSCS meta-analysis: Shi C et al. Transcutaneous spinal cord stimulation on motor function in patients with spinal cord injury: A meta-analysis. Neurorehabilitation and Neural Repair. 2024.

2024 cervical SCI upper extremity review: Singh G et al. Spinal Cord Transcutaneous Stimulation in Cervical Spinal Cord Injury: A Review Examining Upper Extremity Neuromotor Control, Recovery Mechanisms, and Future Directions. Journal of Neurotrauma. 2024.

2026 systematic review cervical SCS: Cervical Spinal Cord Stimulation for Functional Rehabilitation After Spinal Cord Injury: A Systematic Review. Life. 2026;16(1):179.

Electrical stimulation systematic review (PMC): Electrical Stimulation and Motor Function Rehabilitation in Spinal Cord Injury: A Systematic Review. PMC11214755.

SCI statistics: National Spinal Cord Injury Statistical Center. Facts and Figures 2023.

FDA 510(k) clearance explained: Premarket Notification 510(k). FDA.gov.

FDA Breakthrough Device Designation: Breakthrough Device Program. FDA.gov.

Patient resources: Christopher and Dana Reeve Foundation | United Spinal Association | Model Systems Knowledge Translation Center | ClinicalTrials.gov: SCI transcutaneous stimulation

Disclaimer: Health Evidence Digest provides general information about FDA clearances and health research for educational purposes. This content is not a substitute for professional medical advice. ExaStim was cleared through the FDA’s 510(k) pathway. Decisions about rehabilitation technology and treatment approaches for spinal cord injury should be made in consultation with a qualified physiatrist, physical therapist, or occupational therapist experienced in SCI rehabilitation.

April 25, 2026

Wegovy HD: The FDA Just Approved a Semaglutide Dose Three Times Stronger Than Before. Here’s What the Data Actually Shows.

📌 The essentials On March 19, 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg injection, Novo Nordisk) for chronic weight management in adults with obesity (BMI of 30 or higher), or overweight (BMI of 27 or higher) with at least one weight-related condition. This is the highest available dose of injectable semaglutide and the first GLP-1 receptor agonist approved under the Commissioner’s National Priority Voucher (CNPV) program. Prerequisite for use: patients must have tolerated the 2.4 mg Wegovy dose for at least 4 weeks, and additional weight reduction must be clinically indicated. The clinical basis: The STEP UP Phase 3b trial, published in The Lancet Diabetes and Endocrinology in November 2025, showed mean weight loss of 20.7% at 72 weeks with semaglutide 7.2 mg versus 15% with semaglutide 2.4 mg. Approximately 1 in 3 participants lost 25% or more of their body weight. 89% of Wegovy HD participants achieved at least 5% body weight loss versus 38% on placebo. The STEP UP T2D trial in participants with obesity and type 2 diabetes showed mean weight loss of 14.1%. What this approval does not change: Wegovy HD is used alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment. The safety profile is consistent with previously established semaglutide effects, with new attention warranted on altered skin sensation at the higher dose.

When Wegovy (semaglutide 2.4 mg) was approved in June 2021, it represented a meaningful advance in obesity pharmacotherapy. Producing roughly 15% mean body weight loss in clinical trials, it substantially outperformed prior generations of weight management drugs and drove the GLP-1 wave that has since reshaped both prescribing patterns and public conversation around obesity treatment.

But 15% average weight loss, while meaningful, still leaves many patients short of the weight reduction needed to achieve their health goals. For someone starting at 250 pounds, 15% is about 37 pounds. For patients with significant obesity-related comorbidities who need to lose 60 or 80 pounds to meaningfully reduce cardiovascular risk, type 2 diabetes progression, or joint disease burden, the 2.4 mg ceiling was a clinical limitation.

Wegovy HD (semaglutide 7.2 mg), approved March 19, 2026, is Novo Nordisk’s answer to that limitation. It is not a new drug. It is the same semaglutide molecule at a higher dose, with a new clinical program demonstrating that going higher produces meaningfully greater weight loss, with a safety profile consistent with what clinicians and patients already know about semaglutide.

This post covers what the STEP UP trial actually showed, how to read the numbers carefully, who this approval is for, how it fits into the existing semaglutide landscape, and what the CNPV program means for why this approval moved so quickly.

Semaglutide: A Brief Recap of the Mechanism and Existing Approvals

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a class of drugs that mimic the gut hormone GLP-1. GLP-1 is released after eating and signals the pancreas to produce insulin in a glucose-dependent way, suppresses glucagon, slows gastric emptying, and most relevantly for weight management, signals satiety to the brain through receptors in the hypothalamus and brainstem.

At pharmacological doses, semaglutide produces a potent and sustained reduction in appetite and caloric intake that goes well beyond what natural GLP-1 signaling achieves. The weight loss is real and clinically meaningful, but it is dose-dependent: higher doses produce more robust GLP-1 receptor engagement and, in the clinical trials conducted so far, greater weight loss.

The existing semaglutide portfolio in the United States includes:

Product	Dose	Route	Primary indication	FDA status
Ozempic	0.5 mg, 1 mg, 2 mg	Weekly injection	Type 2 diabetes	Approved 2017
Rybelsus	3 mg, 7 mg, 14 mg	Daily oral tablet	Type 2 diabetes	Approved 2019
Wegovy 2.4 mg	2.4 mg	Weekly injection	Chronic weight management	Approved 2021
Wegovy oral 25 mg	25 mg	Daily oral tablet	Chronic weight management	Approved 2025
Wegovy HD 7.2 mg	7.2 mg	Weekly injection	Chronic weight management	Approved March 2026

Wegovy HD joins this portfolio as a step-up option specifically for patients who have been on Wegovy 2.4 mg for at least four weeks and need greater weight reduction. It is not a replacement for the existing 2.4 mg formulation, and it is not the starting point for treatment-naive patients.

The STEP UP Trials: What the Evidence Actually Shows

The FDA approval is based on two Phase 3b trials, both published in The Lancet Diabetes and Endocrinology in November 2025.

STEP UP (obesity without type 2 diabetes)

The STEP UP trial enrolled approximately 1,400 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition. Participants were randomized to once-weekly semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, all as adjuncts to lifestyle intervention, over 72 weeks. Mean baseline body weight was approximately 248 pounds (112.5 kg).

Outcome	Semaglutide 7.2 mg	Semaglutide 2.4 mg	Placebo
Mean body weight loss at 72 weeks	20.7%	~15%	~2 to 3%
Participants losing 25% or more	~1 in 3 (approx. 33%)	Substantially lower	Rare
Participants achieving at least 5% weight loss	89%	Higher than placebo	38%
Statistical significance vs. placebo	Yes (p less than 0.0001)	Yes	Reference
Statistical significance vs. 2.4 mg	Yes (superior)	Reference	—

Source: Wharton S, Freitas P, Hjelmesaeth J, et al. STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8

A mean weight loss of 20.7% from a baseline of approximately 248 pounds translates to roughly 51 pounds of average weight reduction. The finding that approximately 1 in 3 participants achieved 25% or greater weight loss is the number generating the most clinical interest, because it suggests that a meaningful subset of patients on the 7.2 mg dose approaches the weight loss territory previously associated only with bariatric surgery.

For context, Roux-en-Y gastric bypass typically produces 25 to 35% total body weight loss over two years. The overlap between the upper end of pharmacological response with Wegovy HD and surgical outcomes is a genuinely new development in obesity medicine, with implications for how patients and clinicians think about the threshold for surgical consideration.

STEP UP T2D (obesity with type 2 diabetes)

The STEP UP T2D trial enrolled approximately 500 adults with obesity and type 2 diabetes. Semaglutide 7.2 mg produced mean weight loss of 14.1% at 72 weeks compared to placebo. The lower magnitude versus the non-diabetes STEP UP trial is consistent with the pattern seen throughout the semaglutide clinical program: type 2 diabetes attenuates GLP-1-mediated weight loss. This is likely because individuals with established T2D have varying degrees of beta cell dysfunction and altered GLP-1 receptor sensitivity that reduces the drug’s weight-lowering effect. The 14.1% figure is still a clinically meaningful weight loss in a T2D population and substantially better than prior generation weight management drugs.

How to Read the 20.7% Carefully

The 20.7% mean weight loss headline deserves careful interpretation.

It is a mean, not a universal outcome. Mean weight loss describes the average across all participants who completed the trial. Some participants lost substantially more. Some lost less, and some may have lost little or nothing. The 1-in-3 statistic for 25% or greater loss and the 89% statistic for at least 5% loss together give a clearer picture of the distribution: the vast majority of participants achieved meaningful weight loss, and a substantial minority achieved very large weight loss.

72 weeks is not a lifetime. The trial ran for 72 weeks (approximately 17 months). What happens to weight after year two, especially if the drug is discontinued, is a well-established concern across the entire GLP-1 class. Studies of semaglutide 2.4 mg discontinuation show substantial weight regain after stopping treatment. The same pattern should be assumed for Wegovy HD until data proves otherwise. This is a chronic medication for a chronic condition, not a course of treatment with a defined end.

The comparison to 2.4 mg matters for patient selection. The additional weight loss of approximately 5 to 6 percentage points over the existing Wegovy 2.4 mg dose is real and statistically significant, but it comes with additional cost, potentially greater side effect burden, and the requirement for prior tolerance of the lower dose. For patients at or near their weight management goals on 2.4 mg, the step-up may not be necessary or clinically indicated. The label specifically requires that additional weight reduction be clinically indicated before stepping up.

Safety: What’s the Same and What’s New at 7.2 mg

The safety profile of Wegovy HD is broadly consistent with established semaglutide pharmacology. Clinicians and patients familiar with Wegovy 2.4 mg will recognize most of the safety considerations.

Consistent with prior semaglutide experience:

Gastrointestinal effects (nausea, vomiting, diarrhea, constipation, abdominal pain) remain the most common adverse reactions, typically most prominent during dose escalation and tending to diminish with time
The boxed warning for potential thyroid C-cell tumors based on rodent data remains; Wegovy HD is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pancreatitis risk remains a labeled concern; discontinue if suspected
Hypoglycemia risk in patients on insulin or insulin secretagogues

New at the higher dose:

The clinical data from STEP UP identified altered skin sensation, including sensitivity, pain, or burning, at a higher frequency than seen with the 2.4 mg dose. Most cases resolved spontaneously or with dose adjustment, but this is a new signal worth counseling patients about before initiating.

What the label requires for step-up:

Patients must have tolerated semaglutide 2.4 mg for at least four weeks before stepping up to 7.2 mg. This requirement reflects both the clinical logic of demonstrating tolerance at the lower dose and the practical need to allow the most common GI side effects to stabilize before adding a higher dose burden.

The CNPV Connection: Why This Approval Moved Quickly

Wegovy HD was the first GLP-1 receptor agonist to receive a Commissioner’s National Priority Voucher (CNPV) and, notably, the first product to be approved under the CNPV program (the program was used for Wegovy HD before the subsequent psychedelic drug designations announced in April 2026).

As covered in our post on the FDA’s fast-tracking of psychedelic drug programs, a CNPV compresses the FDA review timeline to approximately one to two months from NDA submission versus the standard 10 to 12 months. It does not change the evidentiary standard for approval. The drug still needs to demonstrate substantial evidence of safety and efficacy. It means the FDA will prioritize the review and engage more frequently with the sponsor.

The CNPV for Wegovy HD reflects the FDA’s and the current administration’s positioning of obesity treatment as a national health priority, consistent with the executive orders and policy signals throughout early 2026. Whether this prioritization extends to other obesity and metabolic drugs in the pipeline will be worth watching.

How This Fits Into the GLP-1 and Obesity Treatment Landscape

Wegovy HD does not exist in isolation. It enters a treatment landscape that has been transformed over the past five years by the GLP-1 class and continues to evolve rapidly.

The tirzepatide comparison: Tirzepatide (Zepbound, Eli Lilly), the dual GLP-1/GIP receptor agonist approved in 2023, produces mean weight loss of approximately 20 to 22% in its pivotal SURMOUNT trials at the highest 15 mg dose, with roughly 1 in 3 participants achieving 25% or greater weight loss. The efficacy profile of Wegovy HD at 20.7% mean weight loss with similar distribution now places it in the same general range as tirzepatide, narrowing the efficacy gap that had developed after tirzepatide’s approval. No head-to-head trial comparing the two drugs has been conducted; cross-trial comparisons are unreliable and should not be used to conclude one drug is superior to the other.

The role of step-up therapy: The availability of a higher dose within the semaglutide class provides clinicians with a titration option that did not previously exist for patients on Wegovy who needed more. Previously, the next step beyond 2.4 mg Wegovy for a patient needing greater weight reduction would have been switching to tirzepatide or considering bariatric surgery. Wegovy HD adds an intermediate option within the semaglutide class, which may be preferable for patients who are tolerating semaglutide well and want to maximize their response before considering a class switch.

Availability: Wegovy HD became available at major retail pharmacies, telehealth partners, and through NovoCare/GoodRx channels beginning in April 2026.

For more on how GLP-1 medications are being used beyond their original approved indications, including emerging evidence in PCOS and fertility, see our post on GLP-1 medications and PCOS: what the 2026 research actually shows.

Who Should Consider Wegovy HD and Who Should Not

The FDA label establishes clear parameters for appropriate use. This is not a starting-point obesity treatment, and it is not for everyone who has been on Wegovy 2.4 mg.

May be appropriate for:

Adults with obesity who have been on Wegovy 2.4 mg for at least four weeks, tolerated it well, and still have clinically significant weight loss goals to meet
Patients with obesity-related comorbidities (cardiovascular disease, type 2 diabetes, hypertension, sleep apnea, osteoarthritis) where additional weight loss would materially change the disease course
Patients being evaluated for bariatric surgery who want to explore whether maximal pharmacological therapy achieves sufficient weight loss to meet their goals or reduce surgical risk

Likely not appropriate for:

Treatment-naive patients (must start at lower doses and titrate per established protocol)
Patients who did not tolerate GI side effects at 2.4 mg
Patients at or near their weight management goals on the current dose
Patients with contraindications to semaglutide (personal or family history of MTC or MEN2, history of pancreatitis)
Patients who are pregnant or planning pregnancy in the near term (GLP-1 medications should be discontinued approximately two months before attempting conception)

The cost question: Wegovy HD is a branded medication. List price for Wegovy 2.4 mg has been approximately $1,300 to $1,700 per month without insurance. Wegovy HD pricing has not been separately published as of this post. Novo Nordisk’s NovoCare savings program provides cost assistance for eligible patients. Insurance coverage for higher-dose GLP-1s for obesity (as opposed to type 2 diabetes) remains variable across payers, and prior authorization requirements are common. Patients should verify coverage before starting.

Sources

FDA approval and Novo Nordisk press release: Novo Nordisk A/S: Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss. GlobeNewswire. March 19, 2026.

Novo Nordisk US press release: FDA Approves Novo Nordisk’s New Wegovy HD Injection. PRNewswire. March 19, 2026.

STEP UP primary publication: Wharton S, Freitas P, Hjelmesaeth J, et al; STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8

STEP UP T2D publication: Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948.

AJMC clinical coverage: Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process. AJMC. March/May 2026.

HCPLive approval coverage: FDA Approves Higher Dose Semaglutide (Wegovy HD) Injection 7.2 mg for Obesity. HCPLive. March 2026.

PharmExec coverage: FDA Approves Wegovy HD Injectable Under Accelerated Approval. PharmExec. March 2026.

Wegovy 2.4 mg original FDA approval: FDA approves new drug treatment for chronic weight management in adults. FDA.gov. June 2021.

Semaglutide mechanism reference: Semaglutide. StatPearls. NCBI.

Weight regain after GLP-1 discontinuation: Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. PMC9183237.

Bariatric surgery weight loss reference: Mechanick JI et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. PMC4371744.

Tirzepatide FDA approval: FDA approves novel dual GI peptide receptor agonist for chronic weight management. FDA.gov. November 2023.

Wegovy existing prescribing information: Wegovy prescribing information. accessdata.fda.gov.

NovoCare patient support: novonordisk-us.com/patient-support.html

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about obesity treatment, including whether to step up to Wegovy HD, should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, current medications, and weight management goals. GLP-1 medications should not be discontinued or dose-changed without clinical guidance.

April 24, 2026

The FDA Just Published a Safety Roadmap for Gene Editing Therapies. Here Is What the NGS Guidance Actually Covers and Why It Matters.

The essentials On April 14, 2026, the FDA’s Center for Biologics Evaluation and Research (CBER) published draft guidance titled “Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing.” What it is: a set of recommendations for how companies developing gene editing therapies should use next-generation sequencing (NGS) methods in nonclinical studies to evaluate safety before starting clinical trials. Who it applies to: sponsors developing both ex vivo (cells edited outside the body, then returned) and in vivo (gene editing directly inside the patient’s tissues) human gene therapy products, submitted in support of IND applications and BLAs. What it addresses: sequencing strategies to detect off-target editing events, methods to assess chromosomal integrity, sample selection, analysis parameters, and reporting requirements. Why it matters: this guidance does not approve any drug. It gives sponsors a standardized, scientifically grounded framework for the safety assessment work that must precede clinical trials, reducing regulatory uncertainty and potentially shortening development timelines. Public comment deadline: July 14, 2026. Docket: FDA-2026-D-1255.

Gene editing therapies are among the most technically complex and scientifically promising treatments in modern medicine. The ability to make precise changes to the DNA of living cells has already produced approved therapies for conditions that were previously untreatable, including sickle cell disease, beta-thalassemia, and most recently the first gene therapy for genetic deafness. The pipeline is substantial and growing. But the path from a gene editing candidate to an approved therapy requires rigorous safety assessment, and one of the most important questions that must be answered before any gene editing therapy enters human clinical trials is: what happens when the editing tool goes somewhere it was not supposed to go?

On April 14, 2026, the FDA issued draft guidance specifically addressing how to answer that question. The document provides recommendations for using next-generation sequencing (NGS) methods in nonclinical studies to evaluate safety risks associated with off-target gene editing and loss of genomic integrity. It is a technical document aimed primarily at drug developers and researchers, but the questions it addresses are directly relevant to any patient or family considering a gene therapy clinical trial, and to anyone following the gene therapy field’s trajectory.

This post covers what off-target editing is and why it is a safety concern, how NGS is used to detect it, what the guidance specifically recommends, and why this particular regulatory step matters for the field.

The Problem the Guidance Is Solving: Off-Target Editing

To understand why this guidance exists, it helps to understand the specific risk it is designed to evaluate.

How gene editing works

Gene editing technologies, the most widely discussed being CRISPR-Cas9, work by directing a molecular complex to a specific sequence in the genome, where it makes a targeted cut or modification. In most therapeutic applications, the goal is to correct a harmful mutation, disrupt a disease-causing gene, or insert a therapeutic gene into a specific location.

The molecular machinery that performs this editing uses a guide sequence to find its target in the genome. The human genome contains roughly 3 billion base pairs. The guide sequence is designed to match a unique target, but no biological system is perfect. In some cases, the editing complex finds and modifies sites in the genome that are similar in sequence to the intended target but are not the target. These unintended modifications are called off-target edits.

Why off-target edits are a safety concern

The consequences of off-target edits depend entirely on where they occur in the genome. Many genomic locations are non-functional or contain genes with no role in cell survival or proliferation. An off-target edit in one of these locations may have no detectable consequence. But the genome also contains tumor suppressor genes, proto-oncogenes, and genes that regulate cell cycle progression. An off-target edit that disrupts a tumor suppressor or activates an oncogene could, in theory, initiate a process leading to cancer. This is not a theoretical concern invented by regulators: insertional mutagenesis, a related phenomenon in early viral gene therapy, caused leukemia in several patients in early trials in the 2000s, which fundamentally shaped how the field approaches vector safety.

A separate but related concern is chromosomal integrity. Gene editing tools make cuts in DNA. When the cellular repair machinery processes these cuts, it can sometimes cause larger structural changes: translocations (pieces of one chromosome joining to another), deletions spanning larger regions, or chromosomal rearrangements. These structural changes are assessed separately from single-site off-target edits and require different detection methods.

The FDA guidance addresses both categories of risk.

What Next-Generation Sequencing Is and Why It Is the Right Tool

Next-generation sequencing (NGS), also called high-throughput sequencing, refers to a family of technologies that can read millions or billions of short DNA sequences simultaneously. Unlike the original Sanger sequencing approach, which reads one sequence at a time, NGS generates massive parallel data that can characterize the entire genome of a sample at very high depth, meaning each region is read many times to detect even rare variants.

This depth of coverage is what makes NGS the right tool for detecting off-target editing. Off-target edits may occur in only a small fraction of cells in a treated sample, perhaps 0.1% or less of the total. Detecting these rare events requires reading each genomic region thousands of times to achieve sufficient statistical confidence that a signal is real rather than a sequencing error. The guidance specifically addresses the sequencing depth required for adequate detection of low-frequency off-target events.

NGS is also used for assessing chromosomal integrity. Whole genome sequencing and structural variant analysis can detect larger chromosomal rearrangements that would be missed by targeted approaches.

Short-read versus long-read sequencing

One of the more technically nuanced aspects of the guidance is its discussion of sequencing strategy. Not all off-target events are the same size:

Short stretches of DNA change at off-target sites (insertions, deletions, or base substitutions spanning a few to tens of base pairs) are well-characterized by short-read sequencing, where each read covers approximately 150 to 300 base pairs. This is the most widely used NGS approach.

Longer structural changes (larger deletions, translocations, inversions) may require long-read sequencing approaches, where individual reads span thousands to tens of thousands of base pairs, allowing the detection of events that short-read approaches might miss or mischaracterize.

The guidance advises sponsors to match their sequencing strategy to the type of event being evaluated, rather than applying a single approach to all safety questions. This is a scientifically rigorous position that acknowledges the genuine methodological trade-offs in the field.

What the Guidance Specifically Recommends

The draft guidance covers four main areas: sequencing strategies, sample selection, analysis parameters, and reporting.

Sequencing strategies

Sponsors should use sequencing approaches appropriate to the type of off-target event being assessed. For detection of small insertions and deletions (indels) at off-target sites, short-read approaches are generally appropriate. For detection of larger structural variants and chromosomal integrity assessment, long-read approaches or complementary methods such as optical genome mapping should be considered.

The guidance also addresses sequencing depth, recommending that sequencing be performed at a depth sufficient to detect off-target editing events that may occur at frequencies substantially lower than the on-target edit rate. Because off-target events are typically rare relative to on-target edits, inadequate sequencing depth can produce false-negative results that miss biologically relevant events.

Sample selection

The cells selected for safety assessment should reflect the actual therapeutic product. For ex vivo therapies (where cells are edited outside the body and then infused), the edited cell product itself is the appropriate test material. For in vivo therapies (where the editing tool is delivered directly into the patient), selecting appropriate tissue types for safety assessment is more complex and requires consideration of the delivery route and target tissues.

The guidance acknowledges that for individualized therapies, including personalized therapies being developed for patients with ultra-rare diseases where the specific mutation is unique to one individual, sample availability may be limited. It provides recommendations for how to approach safety assessment in these constrained scenarios.

Analysis parameters and bioinformatics

The guidance addresses how sponsors should approach the computational side of NGS analysis. Raw sequencing data must be processed through bioinformatics pipelines to identify candidate off-target sites, filter sequencing artifacts, and determine which signals represent genuine editing events. The document recommends that sponsors provide sufficient detail about their bioinformatics workflows to allow the FDA to evaluate the rigor of the analysis.

It also addresses how to identify candidate off-target sites to examine in the first place. Computational tools can predict likely off-target sites based on sequence similarity to the guide RNA target, and experimental methods such as GUIDE-seq and CIRCLE-seq can empirically identify editing sites in cell-based systems before sequencing. The guidance recommends using both approaches in combination.

Reporting

The guidance specifies what sponsors should include in their IND and BLA submissions regarding off-target safety assessment. This includes the complete list of candidate off-target sites evaluated, the sequencing methodology and depth, the bioinformatics pipeline used, the results at each evaluated site, and a risk assessment framework for interpreting any off-target events detected.

The Regulatory Context: Where This Guidance Fits

This is not the FDA’s first guidance document on gene editing safety. It builds directly on January 2024 guidance on human gene therapy products incorporating genome editing, which addressed broader nonclinical, clinical, and CMC considerations. The April 2026 draft guidance goes deeper specifically on the NGS methodology question, providing the technical detail that was implicit but not fully specified in the 2024 document.

It also relates to FDA’s February 2026 draft guidance supporting approval of ultra-rare disease therapies, which specifically addresses genome editing and RNA-based therapies including antisense oligonucleotides for conditions affecting so few patients that conventional randomized trial designs are not feasible. The NGS safety guidance applies in those individualized therapy contexts as well, and the February guidance specifically cited it.

The broader policy context is the current administration’s stated priority of accelerating gene therapy development. FDA Commissioner Marty Makary stated at the April 14 release that the guidance provides sponsors with clear, scientifically grounded recommendations for evaluating off-target editing risks using state-of-the-art sequencing technologies and that the agency is serious about moving this ball forward. CBER Director Vinay Prasad described the document as giving sponsors a roadmap for comprehensive safety assessment while supporting the efficient development of these promising therapies.

The practical significance is reduced regulatory uncertainty. Before standardized guidance existed, different sponsors might approach NGS-based off-target assessment very differently, leading to unpredictable FDA feedback and development delays. A clear framework means sponsors can design their safety assessment programs with confidence that the approach will be acceptable to regulators, potentially saving months of back-and-forth early in development.

Why This Matters for Patients and the Gene Therapy Field

Gene editing safety assessment is not a topic that patients following the field need to understand in technical detail. But the existence and quality of this guidance matters for several reasons that are directly relevant to anyone with a personal stake in gene therapy development.

Faster paths to clinical trials. The guidance is specifically designed to help sponsors design adequate nonclinical studies so that IND applications can move forward without extended regulatory delays. For a patient with a genetic disease watching a promising therapy move through development, regulatory efficiency at the nonclinical stage is a meaningful factor in how quickly human trials begin.

Individualized therapies for ultra-rare diseases. The guidance explicitly addresses scenarios where standard approaches cannot be fully applied because the patient population is too small to generate conventional safety datasets. This is directly relevant to the growing number of individualized gene therapy programs, some designed for single patients, where regulatory flexibility and clear scientific standards are both necessary.

The off-target safety question is real. For anyone following the first-in-class gene therapy approvals, including Casgevy (exagamglogene autotemcel) for sickle cell disease and Otarmeni for genetic deafness (covered in our post on the first gene therapy for deafness), understanding that rigorous off-target safety assessment underlies every approved gene editing therapy is reassuring context for both patients and families. This guidance represents the standardization of that rigor across the field.

Transparency through public comment. As a draft guidance, this document is open for public comment through July 14, 2026. Comments can be submitted via Regulations.gov using docket number FDA-2026-D-1255. Academic researchers, patient advocacy organizations, and industry sponsors are all invited to provide feedback that will inform the final guidance. Organizations like the Alliance for Regenerative Medicine and the American Society of Gene and Cell Therapy (ASGCT) will likely submit formal comments representing the field’s collective perspective.

What This Guidance Does Not Do

Clarity on scope matters. This guidance does not:

Approve any gene editing therapy or change the status of any existing approved therapy
Replace the 2024 genome editing guidance, which it supplements rather than supersedes
Address clinical study design, patient safety monitoring during trials, or post-approval safety requirements
Apply to non-genome editing gene therapies (such as AAV gene replacement without editing) except where editing tools are used
Establish a lower bar for approval; it specifies what evidence is needed, not a reduced standard

The guidance is specifically about the nonclinical safety assessment phase: the studies done before human trials begin. Clinical trial safety monitoring, informed consent, adverse event reporting, and post-approval pharmacovigilance are governed by separate frameworks.

Are you a researcher, sponsor, or patient advocate who wants to comment on the draft guidance?

The comment period closes July 14, 2026. Comments can be submitted electronically at Regulations.gov, docket FDA-2026-D-1255. The full draft guidance document is available at FDA.gov. The FDA also encourages sponsors to engage early through INTERACT meetings and pre-IND meetings to discuss specific development strategies before formal submission.

For patients and families following gene therapy development, the National Human Genome Research Institute, the American Society of Gene and Cell Therapy, and the Alliance for Regenerative Medicine maintain current information on approved and investigational gene editing therapies.

Sources

FDA press announcement: FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development. FDA.gov. April 14, 2026.

Draft guidance document: Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry. FDA.gov.

Federal Register docket: FDA-2026-D-1255. Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing. Federal Register. April 15, 2026.

RAPS coverage: FDA drafts guidance on using next-generation sequencing to assess gene therapy safety. raps.org. April 2026.

BioSpace coverage: FDA bolsters bespoke therapy framework with new draft safety guidelines. biospace.com. April 2026.

Clinical Trials Arena: FDA shares guide on genome editing best practices. clinicaltrialsarena.com. April 2026.

European Pharmaceutical Review: New FDA draft guidance to enhance safety of genome editing therapies. europeanpharmaceuticalreview.com. April 2026.

January 2024 predecessor guidance: Human Gene Therapy Products Incorporating Human Genome Editing. FDA.gov. January 2024.

February 2026 ultra-rare disease guidance: Considerations for the Development of Individualized Antisense Oligonucleotide and Genome Editing Therapies. FDA.gov. February 2026.

Comment submission: Regulations.gov docket FDA-2026-D-1255.

Patient and researcher resources: National Human Genome Research Institute: Gene Therapy | American Society of Gene and Cell Therapy | Alliance for Regenerative Medicine | FDA INTERACT meetings

Disclaimer: Health Evidence Digest provides general information about FDA regulatory guidance and health research for educational purposes. This document is a draft guidance, not a final rule, and does not constitute final agency policy until published in final form. This content is not a substitute for professional regulatory, legal, or medical advice. Sponsors developing gene therapy products should consult directly with the FDA through formal meeting procedures regarding specific development programs.

April 23, 2026

Tavneos (Avacopan) and Serious Liver Injury: What Patients and Clinicians Need to Know, Including What the FDA Isn’t Saying Publicly

⚠️ Key Safety Summary: Read This First On March 31, 2026, the FDA issued a Drug Safety Communication identifying 76 cases of drug-induced liver injury (DILI) linked to Tavneos (avacopan), including 8 deaths and 54 hospitalizations. Seven biopsy-confirmed cases involved vanishing bile duct syndrome (VBDS), a potentially irreversible liver condition, and 3 of those were fatal. Median time from starting Tavneos to liver injury onset: 46 days. Most cases occurred within 60 days. Updated monitoring requirements: Patients on Tavneos should have liver function tests every 2 weeks for the first month, then monthly for 5 months. Discontinue immediately if ALT/AST exceed 3 times the upper limit of normal (ULN) or ALP exceeds 2 times ULN. Critical context: The FDA had already requested in January 2026 that Amgen voluntarily withdraw Tavneos from the U.S. market. Amgen refused. The drug remains available.

This story is more complicated than a standard FDA drug safety alert. Tavneos (avacopan) was already under significant regulatory pressure when the March 31, 2026 safety communication was issued, and understanding why the drug is still on the market requires knowing the full context, not just the liver injury numbers.

The liver injury signal is real and serious. Eight people have died. But the situation patients and clinicians are navigating is also one in which a manufacturer has declined a federal request to remove a drug from shelves, both U.S. and European regulators are reviewing the integrity of the clinical trial data that supported the drug’s original approval, and a major watchdog organization is publicly challenging the FDA’s failure to escalate. All of this is happening while people with a serious, life-threatening autoimmune disease continue to be treated with, and in some cases depend on, the drug in question.

Here is the whole picture.

The Disease Tavneos Treats: ANCA-Associated Vasculitis

ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases in which the body’s immune system attacks and destroys small-to-medium blood vessels throughout the body. The two forms Tavneos is approved to treat are granulomatosis with polyangiitis (GPA, formerly called Wegener’s granulomatosis) and microscopic polyangiitis (MPA).

These are serious diseases. Untreated or inadequately managed, they can destroy kidney function, damage the lungs, and be fatal. The standard treatment for decades has involved high-dose glucocorticoids (steroids) combined with immunosuppressants such as cyclophosphamide or rituximab. These regimens work, but carry significant toxicity of their own. Chronic steroid use is associated with infection, bone loss, diabetes, and cardiovascular disease. Any therapy that could reduce steroid burden while maintaining disease control represents a genuine clinical advance.

Avacopan works by blocking the complement C5a receptor, which plays a role in driving neutrophil-mediated inflammation in AAV. The ADVOCATE Phase 3 trial showed it could achieve non-inferior remission rates compared with prednisone tapering at week 26, and superior sustained remission at week 52, with significantly less glucocorticoid exposure. Published in the New England Journal of Medicine in 2021, those results drove FDA approval. That is a clinically meaningful result for a disease where the side effects of standard treatment are themselves a major burden.

The Liver Injury Signal: What the Data Shows

Hepatotoxicity, meaning drug-induced liver injury, was not a surprise finding with avacopan. It was identified in premarket clinical trials and included in the drug’s prescribing information as a warning from the time of approval in 2021. In the ADVOCATE trial itself, 5.4% of patients in the avacopan arm experienced serious adverse events related to liver function, compared with 3.6% in the prednisone arm.

What changed, and what the March 31, 2026 safety communication addresses, are two new and more severe categories of concern that emerged in the postmarketing period:

Category	Number of Cases	Outcomes
All DILI cases (reasonable causal evidence)	76 total	74 serious outcomes
Hospitalizations	54	—
Deaths	8	All fatal by definition
Cholestatic or mixed injury pattern	38 of 60 with lab data	Elevated ALP + bilirubin
Biopsy-confirmed VBDS	7	All hospitalized; 3 fatal
Median time to onset	46 days	Range: 22 to 140 days
Cases from Japan	66 of 76	Largest concentration globally

Source: FDA Drug Safety Communication. March 31, 2026.

What is vanishing bile duct syndrome (VBDS)? VBDS is a rare and serious condition in which the small bile ducts inside the liver are progressively destroyed. Bile, the digestive fluid produced by the liver, can no longer drain properly, leading to a backup of bile acids in the liver and bloodstream. It is called “vanishing” because on liver biopsy, the small intrahepatic bile ducts that are normally present in portal tracts have disappeared. The resulting damage can be permanent and may eventually progress to cirrhosis or liver failure if not caught early. VBDS is most commonly caused by drug-induced liver injury, immune-mediated disorders, infections, and malignancy. It is distinctly different from the transient transaminase elevations seen in many drug reactions. It is a structural injury to the bile duct architecture itself. Clinically, patients typically present with jaundice (yellowing of skin or eyes), pruritus (intense itching that is often worse at night), and fatigue. In the avacopan VBDS cases, the majority occurred within 60 days of starting treatment.

Why Are 87% of Cases From Japan?

The geographic concentration of DILI and VBDS cases is one of the most striking features of this safety signal. Of 76 total DILI cases, 66 were reported from Japan, approximately 87%. Of the 7 biopsy-confirmed VBDS cases, 6 were from Japan.

Amgen has noted that VBDS cases from Japan primarily involved patients aged 65 and older. Several factors may contribute to the geographic pattern, none of which are definitively established:

Pharmacogenomic differences: Japanese patients may have different expression profiles or activity levels for the drug-metabolizing enzymes responsible for avacopan clearance, potentially altering hepatic drug exposure.

AAV epidemiology: MPA is substantially more prevalent in Japan than GPA compared with Western countries, and the two conditions may involve different baseline inflammatory profiles affecting hepatic susceptibility.

Concomitant medications: Patients in Japan may more frequently receive certain co-medications. Antibiotics such as trimethoprim/sulfamethoxazole, commonly given as infection prophylaxis in immunocompromised patients, have themselves been associated with DILI and may interact synergistically.

Post-marketing surveillance intensity: Japan has a notably rigorous pharmacovigilance system, and some of the apparent geographic concentration may reflect more systematic case capture rather than true biological difference.

Age and comorbidity profile: The older age of most Japanese VBDS cases may reflect a population with greater baseline hepatic vulnerability.

A case report published in Annals of Internal Medicine: Clinical Cases documented VBDS in a 74-year-old patient with MPA treated with avacopan, with a Naranjo Adverse Drug Reaction score of 6 (probable causality). That report noted the importance of monitoring compliance: in that case, liver enzyme testing had been inadvertently delayed, which may have contributed to the severity of the injury. It also noted that prior DILI episodes may increase vulnerability to subsequent drug-related liver injury.

The Bigger Story: FDA Requested Withdrawal. Amgen Said No.

The March 31 safety communication cannot be read in isolation. Six weeks earlier, on January 16, 2026, the FDA had privately requested that Amgen voluntarily withdraw Tavneos from the U.S. market. Amgen disclosed this publicly in February, and on January 28 formally informed the FDA it would not comply.

The FDA’s withdrawal request cited two concerns. The first was hepatotoxicity, specifically the emerging DILI and VBDS signal that became the subject of the March safety communication. The second was a data integrity issue: the FDA raised questions about a process followed by ChemoCentryx (the original developer) to re-adjudicate primary endpoint results for 9 of the 331 patients in the ADVOCATE trial, the sole pivotal study supporting avacopan’s approval.

What was the ADVOCATE endpoint re-adjudication controversy? The ADVOCATE trial used the Birmingham Vasculitis Activity Score (BVAS) to assess disease activity. The primary endpoint was remission (BVAS = 0) at week 26. After investigators originally scored certain patients, a post-hoc adjudication committee reviewed and changed the scores for 9 patients. The FDA first raised concerns about this process during the original 2021 review, and the FDA advisory committee vote on avacopan’s approval was close. These disputes were later publicly aired in a civil investor lawsuit (Amgen won in August 2025) and triggered the EMA’s January 2026 safety review of avacopan in Europe. The ADVOCATE re-adjudication issue is about whether the efficacy data supporting avacopan’s approval was handled appropriately, specifically whether changing endpoint scores for 9 patients affected the trial’s outcome assessment in ways that could have influenced regulatory decisions.

Amgen’s response has been consistent: the company maintains that Tavneos has a favorable benefit-risk profile, that liver toxicity is a known and labeled risk, and that more than 7,000 patients have been treated with it since approval. The company has indicated it submitted a proposed label update to the FDA in 2024 to add VBDS to the prescribing information, a request that was still pending at the time of the March 31, 2026 safety communication.

It is also contextually relevant that Tavneos generated $459 million in sales in 2025, growing 62% year-over-year, making it one of Amgen’s fastest-growing products. That commercial context is not dispositive in evaluating Amgen’s position, but it is part of the full picture of why a voluntary withdrawal request would face resistance.

Dr. Robert Steinbrook, Health Research Group Director at Public Citizen, stated in a formal release on March 31, 2026 that if the FDA in January 2026 requested that avacopan be voluntarily withdrawn from the U.S. market, the agency needed to explain publicly why it had not made that request publicly, and why the prescribing information did not yet include a boxed warning for the risk of fatal liver disease. He characterized these as urgent questions for the FDA to answer.

That criticism represents a legitimate and so far unanswered question about regulatory transparency. The FDA’s standard tools when a company declines voluntary withdrawal are limited: the agency can initiate mandatory withdrawal proceedings, but these require formal regulatory steps and take time, and no such proceedings have been announced.

For Patients Currently Taking Tavneos

If you are taking Tavneos for ANCA-associated vasculitis, the most important message is this: do not stop the medication on your own without speaking to your rheumatologist first. Stopping avacopan abruptly without a transition plan in a patient with active GPA or MPA could allow disease flare, which carries its own serious risks including kidney damage.

Symptoms of liver injury: seek care immediately if you develop any of these Unusual fatigue or weakness that is more than your baseline; nausea or vomiting without another clear cause; itching (pruritus), especially if persistent or worse at night; yellowing of your skin or the whites of your eyes (jaundice); light-colored or pale stools; dark, tea-colored urine; pain or swelling in the upper right abdomen. These symptoms can appear within the first six weeks of treatment. Do not wait for your next scheduled appointment. Contact your provider the same day.

If you have concerns about whether to continue Tavneos given the safety communication, that conversation belongs with your rheumatologist specifically. The benefit-risk calculation is individual: it depends on your disease severity, how well your vasculitis is controlled, your liver function baseline, and whether alternative regimens are viable for your situation. The Vasculitis Foundation has issued a patient-facing update on this situation and is a good resource for community support and current information.

Adverse events should be reported to FDA MedWatch at 1-800-332-1088 or online at fda.gov/safety/medwatch.

For Clinicians: Monitoring Protocol and Decision Framework

The FDA’s updated monitoring recommendations are specific and represent an intensification of the original labeling:

Time Period	Monitoring Frequency	Action Threshold
First month of treatment	Every 2 weeks	Discontinue if ALT/AST greater than 3 times ULN, or ALP greater than 2 times ULN
Months 2 to 6	Monthly	Same thresholds; monitor for new symptoms
After 6 months	As clinically indicated	Remain vigilant for late-onset cases
Any time	Immediately on symptoms	Jaundice or pruritus: discontinue and refer to hepatology

Key clinical judgment points for prescribers:

The DILI pattern in most cases is cholestatic or mixed, characterized by elevated alkaline phosphatase (ALP) and total bilirubin rather than isolated transaminase elevation. This pattern can progress more insidiously than hepatocellular injury. Do not wait for transaminase elevation alone to act.

VBDS is a structural, potentially irreversible injury. If a patient develops jaundice or persistent pruritus, discontinue avacopan promptly and refer to hepatology without waiting to see if liver enzymes normalize on repeat testing.

Prior DILI episodes from any cause may increase susceptibility to subsequent drug-induced liver injury. Take a thorough medication and hepatic history before initiating avacopan.

The median onset of 46 days means the highest-risk window falls exactly in the first two months. The biweekly monitoring in month one is not optional in the current regulatory and clinical context.

Document your monitoring compliance carefully. The published VBDS case report noted that a two-week delay in scheduled liver monitoring may have contributed to injury severity in that patient.

For patients with uncontrolled disease where avacopan provides meaningful clinical benefit, the benefit-risk calculation may still favor continuation with rigorous monitoring. For patients in stable remission or with other viable options, the calculus is different. Consult ACR vasculitis guidelines and consider hepatology co-management when initiating or continuing therapy given the current safety signal.

What Happens Next

EMA review

The European Medicines Agency launched a review of avacopan in January 2026, citing concerns about data integrity in the ADVOCATE trial. The EMA will evaluate all available evidence to determine whether the handling of trial data affects the overall benefit-risk profile of avacopan for European patients. That review is ongoing.

FDA mandatory withdrawal authority

When a pharmaceutical company declines a voluntary withdrawal request, the FDA can initiate mandatory withdrawal proceedings under 21 U.S.C. §355(e), but this requires a formal process that includes opportunity for hearing. The FDA has not announced it is pursuing this path for avacopan. Whether and when the agency escalates remains an open question.

Label update (pending)

Amgen submitted a proposed label update in 2024 to add VBDS to the prescribing information. As of the March 31, 2026 safety communication, that label change had not yet been approved. The current label includes a hepatotoxicity warning but does not specifically mention VBDS by name.

Boxed warning

Public Citizen has called for a boxed warning, the FDA’s strongest label alert, reserved for serious or life-threatening risks, for fatal liver disease associated with avacopan. The current label does not carry a boxed warning for hepatotoxicity. Given eight confirmed deaths, the question of whether the FDA will move in this direction in any eventual label update bears watching.

For related coverage of how FDA regulatory tools, including drug safety communications, mandatory withdrawal authority, and label change procedures, work in practice, see our earlier post on what the FDA’s contrasting decisions on camizestrant and vepdegestrant reveal about regulatory evidence standards.

If you are a patient or caregiver navigating this situation:

The Vasculitis Foundation is actively tracking developments and providing patient-centered guidance on the Tavneos situation. The American College of Rheumatology maintains current treatment guidelines for AAV. Adverse events can be reported directly to the FDA MedWatch system at 1-800-332-1088 or online.

Sources

FDA Drug Safety Communication: FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan). March 31, 2026. fda.gov.

Tavneos original FDA approval: FDA approves avacopan for ANCA-associated vasculitis. October 7, 2021. fda.gov.

Amgen prescribing update: Important Update Regarding TAVNEOS (avacopan). Amgen. April 2026.

ADVOCATE Phase 3 trial: Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384:599-609.

ADVOCATE trial registration: NCT02994927. ClinicalTrials.gov.

VBDS case report: Annals of Internal Medicine: Clinical Cases. Avacopan Causing Vanishing Bile Duct Syndrome in an Adult Patient With Microscopic Polyangiitis. 2024. doi:10.7326/aimcc.2024.0602

Withdrawal controversy: Medscape. What’s at Issue in the FDA’s Request to Withdraw Avacopan? February 23, 2026.

Medscape alert coverage: Medscape. FDA Issues Alert on Liver Injuries Linked to Vasculitis Drug, Following Withdrawal Request. March 31, 2026.

Amgen refusal: Pharmaphorum. Amgen baulks at FDA request to withdraw Tavneos. February 2026.

Public Citizen statement: Public Citizen. FDA’s Avacopan Alert Raises More Questions Than It Answers. March 31, 2026.

EMA review: European Medicines Agency. EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA. January 30, 2026.

Vasculitis Foundation patient update: Important Information for the Vasculitis Community Regarding TAVNEOS (avacopan). vasculitisfoundation.org. April 2026.

The Rheumatologist: Kaufman MB. Avacopan Under Scrutiny by FDA, EMA Due to Data Concerns. February 21, 2026. the-rheumatologist.org.

ACR vasculitis guidelines: American College of Rheumatology. Guidelines for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. rheumatology.org.

MedWatch adverse event reporting: FDA MedWatch Safety Reporting Portal. fda.gov/safety/medwatch.

Patient resources: Vasculitis Foundation | American College of Rheumatology | FDA MedWatch | NIAMS Vasculitis Information

Disclaimer: Health Evidence Digest provides general information about drug safety communications and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Patients should not make changes to their medication without consulting their healthcare provider. All clinical decisions should account for individual patient circumstances, disease severity, and current treatment guidelines.

April 22, 2026

One in Three Women with Premature Ovarian Insufficiency Gets the Hormone Therapy They Need. Here Is Why That Number Should Be Much Higher.

The essentials: A study published in Menopause, the journal of The Menopause Society, analyzed data from more than 255,000 patients and found that only 36% of women diagnosed with premature ovarian insufficiency (POI) received hormone therapy, despite consistent international guidelines recommending it. The study was conducted in tertiary hospitals in Saudi Arabia, providing real-world prescribing data from a region where HT underuse is documented but less studied. The gap matters because women with POI who do not receive hormone therapy until the average age of natural menopause face substantially higher risks of osteoporosis, cardiovascular disease, cognitive decline, and mood disorders compared with women who reach menopause naturally after age 40. The finding is consistent with what the NIH and multiple research groups have documented in U.S. and European populations: HT underuse in POI is a global problem, not a regional one.

Premature ovarian insufficiency is not the same as early menopause, though the terms are often used interchangeably. It is a clinical diagnosis made when a woman loses normal ovarian function before the age of 40, with ovarian function sometimes fluctuating rather than ceasing entirely. About 1 in 100 women is affected. Many are in their 20s and 30s. Some are teenagers. Most receive a diagnosis only after months or years of being told their irregular periods are stress, overexercise, or a thyroid issue.

When the diagnosis finally arrives, it carries consequences that extend well beyond infertility, which tends to dominate the conversation. Women with POI face the same estrogen deficiency that women in natural menopause experience, but they face it decades earlier, and they face it for far longer. The cumulative health burden of that estrogen deficit over 10 to 20 additional years is substantial, and it is largely preventable with hormone therapy.

A new study published in Menopause in January 2026 quantifies how large the treatment gap actually is. Only 36% of women diagnosed with POI received hormone therapy. That means roughly two out of three women with a condition that consistently generates international guideline recommendations for HT are not getting it.

What POI Is and Why It Is Different from Natural Menopause

Premature ovarian insufficiency is defined by two criteria: age younger than 40, and biochemical confirmation of ovarian dysfunction, typically elevated follicle-stimulating hormone (FSH) levels on two measurements taken at least four weeks apart. The ovaries have not failed completely in most cases. Intermittent ovarian activity and even spontaneous pregnancy can occur in 5 to 10% of women after diagnosis. But sustained, predictable hormone production has been disrupted.

The distinction from natural menopause matters for treatment and prognosis. In natural menopause, the gradual decline in estrogen production reflects a process that unfolds over the expected lifespan, and cardiovascular, bone, and neurological systems have had decades to adapt. In POI, the estrogen deficit arrives abruptly and at an age when those systems have not yet had that adaptation. The resulting long-term risks are not equivalent.

The long-term health consequences of untreated POI Bone: Osteoporosis risk is substantially elevated in women with POI, driven by the loss of estrogen’s protective effect on bone mineral density. Women with POI have significantly lower bone density than age-matched peers, and the risk of fragility fractures accumulates with each decade of untreated estrogen deficiency. Even in the study reviewed here, which found that 6.8% of participants had a documented diagnosis of osteopenia and 4.9% had osteoporosis, hormone therapy uptake in those women remained low. Cardiovascular: Estrogen has cardioprotective effects, and its premature loss is associated with higher rates of cardiovascular disease, hypertension, and adverse lipid profiles in women with POI compared with age-matched controls. Women with POI who do not receive HT have been shown to have cardiovascular risk profiles closer to those of age-matched men than to age-matched women who entered menopause at the expected time. Cognitive and neurological: There is growing evidence that estrogen plays a role in brain health and cognitive function, and some studies suggest increased risk of cognitive decline and dementia in women with untreated POI. The mechanism is not fully established, but the long window of estrogen deficiency is a plausible contributor. Mood and mental health: Depression, anxiety, and sexual dysfunction occur at higher rates in women with POI than in age-matched controls. Estrogen has direct effects on neurotransmitter systems involved in mood regulation, and the psychological burden of the diagnosis itself, including grief over fertility loss and uncertainty about long-term health, compounds the biological effects.

What the Study Found

The study, published in the January 2026 issue of Menopause, was conducted across tertiary hospitals in Saudi Arabia. Researchers analyzed data from more than 255,000 patients with the objective of determining how often hormone therapy is prescribed for women with POI and what factors are associated with receiving it.

Key findings:

The prevalence of POI among women who underwent FSH testing was 5.05%. This is higher than the 3.5% global estimate from prior systematic reviews, though the difference likely reflects selection bias: women being tested for FSH in tertiary settings are more likely to have symptoms suggestive of ovarian dysfunction than the general population.

Of women diagnosed with POI, only 36% received hormone therapy. That is the central number, and it is consistent with underuse estimates from other regions. A previous systematic review found that across multiple countries, hormone therapy initiation rates in women with POI range from approximately 35 to 50%, with wide variation based on geography, healthcare system, and provider specialty.

Amenorrhea (absence of menstrual periods) was the most common presenting symptom, affecting 42.4% of participants. This is clinically important context: amenorrhea is the symptom most likely to prompt FSH testing and subsequent POI diagnosis, but it is also a symptom that can persist for years without triggering a formal workup in healthcare systems where irregular periods are routinely attributed to stress, thyroid dysfunction, or other causes.

Hormone therapy uptake remained low even in the subset of women who already had a documented diagnosis of bone density loss: 6.8% with osteopenia and 4.9% with osteoporosis were identified in the cohort, and HT use remained below expected rates in these groups. This finding is particularly striking because bone protection is one of the most clearly established benefits of HT in POI and one where the risk-benefit calculation most clearly favors treatment.

Geographic context: This study was conducted in Saudi Arabia, and regional differences in hormone therapy use are well established and real. Cultural, religious, and healthcare system factors influence prescribing patterns in ways that limit direct extrapolation. However, the authors note that the NIH and multiple U.S.-based research groups have documented comparably low HT utilization in American women with POI, and the ESHRE POI guideline explicitly addresses the underuse problem as a global phenomenon.

The WHI Shadow: Why Fear of Hormone Therapy Has Outlasted the Evidence That Created It

To understand why two-thirds of women with POI are not receiving a treatment that guidelines consistently recommend, you need to understand what happened in 2002.

The Women’s Health Initiative (WHI) was a large, landmark study of hormone therapy in postmenopausal women. In 2002, the combined estrogen-progestin arm of the trial was stopped early after researchers found increased risks of breast cancer, heart disease, stroke, and blood clots. The results generated enormous media coverage and fundamentally shifted prescribing behavior. HT use in menopausal women plummeted within months and has never fully recovered.

The problem is that the WHI findings were widely misapplied. The study enrolled women with an average age of 63, the majority of whom were more than 10 years past menopause. The findings were about hormone therapy initiated years after menopause in women for whom estrogen replacement was not restoring a physiological state but adding hormones to a body that had long since adapted to their absence. The results do not apply to women in their 20s and 30s with POI, in whom HT is restoring estrogen levels to what would naturally be present at their age.

Major medical organizations have tried to correct this misapplication. The Menopause Society’s 2023 position statement explicitly states that for women younger than 40 with POI, HT is recommended until the average age of natural menopause (approximately 51) in the absence of contraindications, and that the risks identified in the WHI do not apply to this population. The ESHRE POI guideline, the NICE guideline on menopause, and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists all say the same thing.

The message has not reached clinical practice consistently, and it has reached patients even less.

What the Guidelines Actually Say

International clinical guidelines on POI are consistent in their core recommendation: hormone therapy should be offered to women with POI until approximately the average age of natural menopause, roughly 51 years in most populations, unless there is a specific contraindication.

The rationale is straightforward. HT in POI is not pharmacological intervention in the way that HT in a 60-year-old is. It is replacement of hormones that the body would naturally be producing at that age but is not. The risks associated with HT in older postmenopausal women do not apply because the frame of reference is different: POI in a 28-year-old is not the same biological situation as menopause in a 63-year-old.

The specific formulation of HT in POI is also distinct from what is typically used in natural menopause. Estrogen doses needed to restore physiological levels in women with POI are generally higher than standard low-dose HT formulations used in natural menopause. Many standard preparations are designed for symptom management in older postmenopausal women at the lowest effective dose. Women with POI need estrogen levels comparable to what their peers have naturally, which may require different dosing strategies and routes of administration.

Women with an intact uterus also need progestogen to protect the uterine lining from unopposed estrogen stimulation. The choice of progestogen formulation matters: micronized progesterone (body-identical progesterone) appears to carry a lower breast cancer risk signal than synthetic progestins based on current evidence, though the absolute risk differences in young women are small.

Barriers to Treatment: What the Research Points To

The study’s authors identify two primary drivers of HT underuse in POI: provider knowledge gaps and patient fears. The research literature supports both.

Provider factors: Many women with POI are seen by general practitioners or gynecologists without subspecialty training in reproductive endocrinology or menopause medicine. Studies in multiple countries have found that a substantial proportion of providers are unfamiliar with current POI guidelines, underestimate the long-term health risks of untreated POI, or have not updated their prescribing practices since the 2002 WHI publication. Diagnosis itself is often delayed: the average time from first symptom to POI diagnosis has been estimated at 4 to 6 years in some studies, reflecting both the intermittent nature of ovarian function in some cases and the tendency to attribute symptoms to other causes.

Patient factors: Fear of breast cancer is the dominant barrier on the patient side, a direct legacy of the 2002 WHI coverage. Women who decline HT for POI often cite cancer risk as their primary concern, even though the evidence does not support elevated breast cancer risk from physiological estrogen replacement in a young woman with POI. Addressing this misunderstanding requires time, clear communication, and a provider who is confident explaining why the WHI findings do not apply to a 32-year-old whose ovaries stopped working.

Fertility concerns can also complicate the HT conversation in a counterproductive way. Some women with POI delay hormone therapy out of concern that it will reduce their already limited chances of spontaneous pregnancy. Current evidence does not support this concern: HT does not suppress the intermittent ovarian activity that underlies spontaneous ovulation in POI, and the cardiovascular and bone protection benefits of starting HT early outweigh theoretical fertility concerns in most cases.

What Women with POI Should Know

If you have been diagnosed with POI, or are being evaluated for it, here is what the current evidence supports:

Hormone therapy is recommended. Every major international guideline recommends HT for women with POI until approximately age 51, unless a specific contraindication exists such as a personal history of hormone-receptor-positive breast cancer or a known high-risk thrombophilia.

The WHI does not apply to you. The risks identified in that study are not relevant to estrogen replacement in women whose ovaries stopped functioning before age 40. This is worth discussing explicitly with your provider if concern about those findings is part of the conversation.

The dose may need to be higher than standard HT. Low-dose preparations designed for older postmenopausal women may not restore your estrogen to physiological levels. Ask your provider whether the formulation and dose is appropriate for your age rather than simply the lowest available option.

Delaying treatment has real consequences. Every year without HT in POI is a year of accelerated bone loss, cardiovascular risk accumulation, and potential neurological effects. The benefits of starting HT early and continuing it to the average age of natural menopause are well established in the guideline literature.

Seek a provider with POI or reproductive endocrinology experience. Not all gynecologists have current, guideline-concordant knowledge about POI management. The Menopause Society’s practitioner finder can help identify providers with menopause medicine certification. If you are also navigating fertility questions, a reproductive endocrinologist is the appropriate specialist.

For related women’s health coverage on Health Evidence Digest, see our posts on GLP-1 medications and PCOS fertility research in 2026, new 2026 cervical cancer screening guidelines including self-collection, and the first non-hormonal endometriosis drug entering clinical trials.

Sources

Primary study: Use of hormone therapy in patients with premature ovarian insufficiency in tertiary hospitals in Saudi Arabia. Menopause. Published January 21, 2026.

The Menopause Society press release: Hormone Therapy Underused in Women With Premature Ovarian Insufficiency. menopause.org. January 21, 2026.

ESHRE POI Guideline: Management of women with premature ovarian insufficiency. European Society of Human Reproduction and Embryology. 2024.

Menopause Society position statement: The 2023 Menopause Society Position Statement on Hormone Therapy. menopause.org.

NICE guideline on menopause: Menopause: diagnosis and management. NICE guideline NG23. nice.org.uk.

POI systematic review and long-term outcomes: Golezar S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019.

POI clinical review: Webber L, et al. POI: pathophysiology, presentation, diagnosis, and management. BMJ. 2016.

Cognitive effects of early menopause: Phung TK, et al. Dementia risk in women with premature ovarian insufficiency and early menopause. PMC9585583.

WHI overview: Women’s Health Initiative. National Heart, Lung, and Blood Institute.

NICHD POI resource: Premature Ovarian Insufficiency. nichd.nih.gov.

Menopause Society practitioner finder: Find a Menopause Healthcare Practitioner. menopause.org.

Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about hormone therapy for premature ovarian insufficiency should be made in consultation with a qualified healthcare provider who can evaluate individual health history, contraindications, and treatment goals.

April 21, 2026

A Fatal Childhood Disease Has No Treatment. A Gene Therapy with Eight Years of Data Is Now Under FDA Review. Here Is What the Evidence Shows.

📌 The essentials On April 2, 2026, the FDA accepted for review the resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy developed by Ultragenyx Pharmaceutical for Sanfilippo syndrome Type A (MPS IIIA). PDUFA date: September 19, 2026. Regulatory history: the FDA previously granted UX111 Priority Review in February 2025. The BLA was originally submitted, received a Complete Response Letter, and was resubmitted in January 2026 with additional long-term clinical data agreed upon with the FDA. The clinical basis: up to 8 years of follow-up showing sustained, significant reductions in CSF heparan sulfate and continued functional improvements compared with natural history, including a 23.2-point Bayley-III cognitive gain (p less than 0.0001) in early-stage patients and median 63.98% CSF heparan sulfate reduction (p less than 0.001). If approved: UX111 would be the first approved therapy for MPS IIIA. There are currently no disease-modifying treatments for this condition. The disease: Sanfilippo syndrome Type A is a rare, fatal lysosomal storage disorder causing progressive neurodegeneration in young children, with a median life expectancy of approximately 15 years.

Some diseases are called rare because they affect a small number of people. Sanfilippo syndrome is rare in a different sense. It is rare in the way that makes people who learn about it stop mid-sentence. It is a genetic disease that affects young children, causes their nervous systems to progressively deteriorate, and kills most of them in their teenage years. It has no approved treatment.

Children with Sanfilippo syndrome often appear developmentally normal in early infancy. The first signs, typically behavioral changes and developmental regression, usually emerge between ages 2 and 6, after parents have already formed complete pictures of who their child is. Then the regression accelerates. Language disappears. Motor skills deteriorate. Most children lose the ability to walk, eat independently, and communicate. Median life expectancy is approximately 15 years.

On April 2, 2026, Ultragenyx Pharmaceutical announced that the FDA has accepted for review its resubmitted Biologics License Application for UX111 (rebisufligene etisparvovec), a one-time intravenous gene therapy for Sanfilippo syndrome Type A. The FDA set a PDUFA action date of September 19, 2026. The clinical data behind this application includes up to eight years of follow-up in treated patients, and the results represent the most robust evidence ever generated for a potential treatment of this disease.

This post covers what Sanfilippo syndrome Type A is and what it does to the children who have it, how UX111 works, what the clinical trial data actually shows, the regulatory history that preceded this acceptance, and what families and clinicians need to understand about where the program stands.

What Sanfilippo Syndrome Type A Is

Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a group of four subtypes (A, B, C, and D) caused by different enzyme deficiencies, all of which result in the accumulation of heparan sulfate, a long-chain sugar molecule, within cells throughout the body. The brain is particularly affected because neurons are especially sensitive to this toxic accumulation.

Sanfilippo syndrome Type A (MPS IIIA) is the most common and most severe subtype. It is caused by mutations in the SGSH gene, which encodes the enzyme sulfamidase (also called heparan-N-sulfatase). Without functional sulfamidase, heparan sulfate cannot be broken down and accumulates progressively in lysosomes throughout neural and other tissues.

The disease follows a characteristic three-phase progression:

Phase 1: Developmental delay or regression, typically appearing between ages 2 and 6. Behavioral symptoms are often prominent, including hyperactivity, aggression, and sleep disturbance. This phase can last several years.

Phase 2: Severe neurological decline. Language is lost, motor skills deteriorate, and seizures become common. Behavioral symptoms often intensify before this phase.

Phase 3: Final stage, characterized by profound neurological impairment, loss of ambulation, and complete dependence for all care. Death typically occurs between ages 10 and 20 in most patients, though some survive longer.

An estimated 3,000 to 5,000 children worldwide have MPS IIIA. In the United States, approximately 1 in 100,000 live births is affected. There are currently no approved disease-modifying treatments in any country.

The heparan sulfate accumulation problem: why it is so damaging and so hard to treat Heparan sulfate (HS) is a normal component of the extracellular matrix and cell surface in virtually all tissues. The breakdown of heparan sulfate requires a sequential series of enzymes; if any one of them is deficient, partially broken-down HS fragments accumulate in lysosomes. The accumulation is not static: it worsens progressively with age as the substrate burden grows. In the brain, heparan sulfate accumulation triggers inflammatory pathways, impairs autophagy (the cellular waste-disposal process), and causes progressive neuronal death. Because the blood-brain barrier prevents large proteins like enzyme replacements from reaching the central nervous system in therapeutic concentrations, the standard treatment approach for many lysosomal storage disorders, enzyme replacement therapy (ERT), has not been effective for MPS IIIA. ERT can address peripheral manifestations but cannot adequately cross the blood-brain barrier to address the primary site of pathology. This is why gene therapy, which can deliver a functional gene directly into cells that will express the enzyme continuously, is being pursued as the mechanism most likely to address the neurological aspects of the disease.

How UX111 Works

UX111 (rebisufligene etisparvovec) is an adeno-associated virus serotype 9 (AAV9) gene therapy. AAV9 is selected for CNS applications because it can cross the blood-brain barrier and transduce neurons efficiently after intravenous administration, which is the critical property that makes it suitable for addressing the neurological pathology in MPS IIIA.

The therapy delivers a functional copy of the SGSH gene under the control of a promoter designed to drive expression in cells throughout the body, including the central nervous system. Once transduced, cells begin producing functional sulfamidase enzyme, which can then begin breaking down the accumulated heparan sulfate substrate. The enzyme produced in transduced cells can also be taken up by neighboring, non-transduced cells through a process called cross-correction, extending the therapy’s reach beyond the cells directly infected by the viral vector.

UX111 is administered as a single intravenous infusion. It is not a continuous therapy requiring repeated dosing. The one-time administration is designed to provide durable gene expression over years, which is both the key clinical advantage and one of the central questions the FDA’s review will focus on: how durable is the effect, and for how long?

The therapy was originally developed by Abeona Therapeutics before being transferred to Ultragenyx, which completed the clinical development program and built out manufacturing capacity. If approved, UX111 will be manufactured entirely within the United States at Andelyn Biosciences in Columbus, Ohio, and at Ultragenyx’s gene therapy manufacturing facility in Bedford, Massachusetts.

The Clinical Evidence: Eight Years of Follow-Up Data

The BLA accepted by the FDA on April 2, 2026 is built on a clinical program that has been running since 2015. The primary study is NCT02716246, a Phase 1/2/3 gene transfer clinical trial conducted across multiple sites.

The data package includes two categories of evidence that together form the basis for the accelerated approval application: biomarker data (cerebrospinal fluid heparan sulfate levels) and functional clinical data across multiple developmental domains.

Biomarker evidence: CSF heparan sulfate reduction

Cerebrospinal fluid heparan sulfate (CSF-HS) is the primary biomarker for MPS IIIA disease activity. Elevated CSF-HS directly reflects the accumulation of toxic substrate in the CNS. Sustained reduction of CSF-HS is the proposed intermediate clinical endpoint for the accelerated approval, as agreed with the FDA during the prior clinical review.

Across the trial cohort, UX111 produced a median reduction of approximately 63.98% in CSF-HS levels (p less than 0.001) over a median follow-up of approximately 4.8 years. An earlier data analysis using time-normalized area under the curve (AUC) methodology to capture cumulative substrate reduction across the full follow-up period found a mean reduction of 63% (p less than 0.0001). The reductions were sustained and not limited to early post-treatment timepoints, supporting the durability of the gene expression.

Functional clinical data: separation from natural history

Because MPS IIIA is a progressive disease with a well-characterized natural history trajectory, treated patients can be compared to what the expected course of the disease would be without intervention. This natural history comparison is the primary method for evaluating functional benefit in the absence of a randomized placebo-controlled trial, which is not ethically feasible in a fatal pediatric disease.

Outcome measure	Finding	Statistical significance
Bayley-III cognitive composite (early-stage patients)	+23.2-point gain versus natural history	p less than 0.0001
Communication skills retention	Maintained beyond ages when untreated peers typically lose language	Significant separation from natural history
Ambulation	Continued walking beyond expected loss age in many treated patients	Significant separation from natural history
Self-feeding	Retained in treated patients beyond typical loss age in untreated peers	Significant separation from natural history
CSF heparan sulfate reduction	Median 63.98% reduction	p less than 0.001
Follow-up duration	Up to 8 years; median approximately 4.8 years	Longest follow-up in any MPS IIIA therapeutic program

Source: Ultragenyx press release February 3, 2026. WORLDSymposium 2026 presentation. NCT02716246.

The 23.2-point Bayley-III cognitive gain in early-stage patients is the most clinically striking number in the dataset. The Bayley Scales of Infant and Toddler Development (Bayley-III) is a standardized developmental assessment. A 23-point gain against a natural history trajectory that is declining represents the children treated with UX111 not just slowing their decline but functioning meaningfully better than where their disease would have taken them without treatment.

The consistency of the results across age groups and disease severity levels at enrollment is also significant. Children who were treated at earlier stages of disease showed the largest functional gains, which is consistent with the biology: gene therapy that reduces substrate accumulation is more effective when there is less existing neuronal damage to overcome. But even children treated at more advanced disease stages showed meaningful separation from natural history in terms of skill retention.

Ultragenyx’s Chief Scientific Officer characterized the data at the time of the BLA resubmission as demonstrating “a remarkable and unprecedented separation from the natural history of Sanfilippo syndrome through more than eight years of follow-up, with children in their teens retaining skills at an age when many of their untreated peers have sadly lost them.”

The Regulatory History: Why This Is a Resubmission

Understanding why this is a resubmitted BLA rather than an initial submission requires knowing what happened the first time.

Ultragenyx originally submitted the UX111 BLA to the FDA and received a Complete Response Letter, meaning the FDA determined the application was not approvable as submitted and identified deficiencies that needed to be addressed before approval could be considered.

The specific deficiencies cited in the CRL centered on the evidentiary standard for the intermediate clinical endpoint supporting accelerated approval. The FDA’s position was that additional long-term clinical data on neurological function would be needed to support the proposed surrogate endpoint of CSF-HS reduction as reasonably likely to predict clinical benefit. Ultragenyx and the FDA agreed during subsequent discussions on what additional data would be required, and the company continued following patients and collecting data.

The resubmission in January 2026, accepted on April 2, 2026, includes those agreed-upon longer-term data. The FDA’s acceptance with a PDUFA date confirms that the agency considers the resubmission complete and the identified deficiencies addressed. It does not guarantee approval but indicates that the evidentiary package meets the threshold for full review.

The FDA granted the UX111 BLA Priority Review in February 2025, which compresses the review timeline from the standard 12 months to 6 months. The September 19, 2026 PDUFA date reflects Priority Review timing from the January 2026 resubmission.

What accelerated approval means for UX111 Accelerated approval is an FDA pathway that allows approval of drugs for serious conditions based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit, rather than requiring demonstration of direct clinical benefit in pivotal trials. For UX111, the proposed surrogate endpoint is CSF heparan sulfate reduction, which is biologically linked to the neurological pathology: less HS accumulation in the CNS should translate to less neuronal damage and better preservation of function. The additional clinical data in the resubmission, showing functional gains on Bayley-III and other measures alongside the CSF-HS reductions, provides supporting evidence that the surrogate is tracking real neurological benefit. If UX111 receives accelerated approval, continued approval would be contingent on verification of clinical benefit in a confirmatory trial. This is the standard condition of accelerated approval across all indications. For a disease as rare as MPS IIIA, designing and executing a confirmatory trial after approval raises its own logistical questions that the field will need to navigate.

Regulatory Designations and Their Significance

UX111 holds multiple regulatory designations in the United States and Europe, each reflecting a different aspect of its development program:

Designation	Grantor	What it means
Priority Review	FDA (February 2025)	Compresses review timeline to 6 months from standard 12
Regenerative Medicine Advanced Therapy (RMAT)	FDA	Intensive FDA guidance and interaction; eligibility for accelerated approval, priority review, rolling review
Fast Track	FDA	More frequent FDA meetings; rolling review eligibility
Rare Pediatric Disease	FDA	Eligible for priority review voucher upon approval
Orphan Drug	FDA	7 years market exclusivity; tax credits for clinical development
PRIME designation	EMA	Enhanced early dialogue and guidance for promising medicines
Orphan Medicinal Product	EMA	European market exclusivity for 10 years

The Rare Pediatric Disease designation is worth specific attention. If UX111 is approved under this designation, Ultragenyx would receive a Priority Review Voucher (PRV) that can be used by the company or sold to another pharmaceutical company to accelerate a different drug’s FDA review. These vouchers have sold for hundreds of millions of dollars and represent a significant financial incentive structure that Congress created specifically to encourage development of therapies for rare pediatric diseases.

Safety: What the Clinical Program Shows

Across the clinical trials with follow-up of up to 8 years, UX111 has maintained what Ultragenyx describes as an acceptable and favorable safety profile. No unexpected or serious safety signals have been identified in the long-term follow-up data.

The general safety considerations for AAV9 gene therapy apply to UX111:

Immune responses: AAV capsid can trigger immune responses. Patients with pre-existing immunity to AAV9 (neutralizing antibodies) are typically screened and may be ineligible for treatment. The immune response to the viral vector is a key safety monitoring point in the weeks immediately following infusion.

Liver enzyme elevations: Transient elevations in liver enzymes are a known effect of AAV gene therapies, reflecting immune-mediated responses to transduced hepatocytes. Corticosteroid prophylaxis is used to manage these responses and has been incorporated into the treatment protocol.

Long-term gene expression: While durable expression is the goal, the long-term behavior of AAV9 in pediatric patients who are still growing and developing is an area of ongoing monitoring. The 8-year follow-up data is reassuring on this point but continued surveillance is appropriate.

Genotoxicity: Insertional mutagenesis from AAV vectors is considered low-risk compared to integrating viral vectors, but it is not zero, and long-term registry follow-up is standard practice for gene therapy recipients.

The full prescribing information, when and if it is issued, will contain the complete safety profile from the clinical program.

What This Means for Families Affected by MPS IIIA

If your child has been diagnosed with Sanfilippo syndrome Type A, or you are supporting a family navigating this diagnosis, here is what the September 19, 2026 PDUFA date means and does not mean:

BLA acceptance is not approval. The FDA has accepted the application for review and set a decision target date. The agency will conduct its own independent analysis of all submitted data. The outcome could be approval, a request for additional information, or another Complete Response Letter.

The PDUFA date is a target, not a guarantee. Decisions can come on or before the PDUFA date. The FDA could also extend the review if it identifies issues requiring additional analysis.

Earlier treatment appears to produce better outcomes. The clinical data consistently shows that children treated at earlier disease stages had larger functional gains. If UX111 is approved, treatment timing relative to disease stage will likely be a central clinical consideration.

No treatment is currently approved. While the BLA is under review, MPS IIIA remains without any disease-modifying approved therapy. Families should continue working with metabolic disease specialists at centers with lysosomal storage disorder expertise.

Clinical trial participation remains available. NCT02716246 continues to follow existing participants. Families interested in clinical trial options can search ClinicalTrials.gov for currently enrolling studies.

The most current patient-facing resources are maintained by the National MPS Society, which provides disease information, family support, and physician referral guidance. The NORD rare disease database also maintains a current overview of MPS IIIA. The NIH Genetic and Rare Diseases Information Center provides clinical and research information including ongoing trial listings.

For context on how the FDA has approached other gene therapy approvals for rare pediatric diseases, including the recent approval of the first gene therapy for genetic deafness, see our post on Otarmeni and what the first gene therapy approval under the CNPV program means for the field.

Sources

FDA BLA acceptance press release: Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA). GlobeNewswire. April 2, 2026.

BLA resubmission press release: Ultragenyx Resubmits Biologics License Application for UX111. Ultragenyx IR. January 30, 2026.

Long-term clinical data press release: Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS. GlobeNewswire. February 3, 2026.

CSF-HS correlation data: Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid. Ultragenyx IR.

Clinical trial registration: NCT02716246. Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.HsGSH for MPS IIIA. ClinicalTrials.gov.

MPS IIIA disease overview: Mucopolysaccharidosis Type IIIA. StatPearls. NCBI.

Heparan sulfate and MPS IIIA biology: Heparan Sulfate Proteoglycans in Neurodegeneration. PMC5026768.

NIH GARD MPS IIIA: Mucopolysaccharidosis type IIIA. rarediseases.info.nih.gov.

Accelerated approval pathway: Accelerated Approval. FDA.gov.

RMAT designation: Regenerative Medicine Advanced Therapy Designation. FDA.gov.

Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

Bayley-III assessment: Bayley Scales of Infant and Toddler Development. PMC6052512.

ERT limitations in MPS: Enzyme Replacement Therapy for Lysosomal Storage Disorders. PMC5814258.

Patient resources: National MPS Society | NORD: MPS III | NIH GARD | ClinicalTrials.gov: MPS IIIA

Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. UX111 (rebisufligene etisparvovec) is not yet FDA-approved. Families navigating a Sanfilippo syndrome Type A diagnosis should work with a metabolic disease specialist at a center with lysosomal storage disorder expertise.

April 20, 2026